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ABSTRACT 
Saponins are naturally occurring glycosides that are widely distributed in the plant 
kingdom and lower marine organisms. Saponins consist of a carbohydrate chain attached 
to either a steroid or triterpene aglycone. Diosgenyl saponins are among the most 
abundant steroidal saponins and have attracted much attention for a host of varying 
biological activities. In recent years, diosgenyl saponins have demonstrated anticancer 
activity in a variety of cancer cell lines. The antitumour effect of diosgenyl saponins is 
shown to be through apoptosis. 
Structural complexity and limited accessibility have led to a poor understanding of the 
mechanism of diosgenyl saponin anticancer activity. The position of attachment of 
moieties on the aglycone and the variety of the side chains are all factors that contribute 
to the complexity of a structure activity relationship study. Monosaccharide diosgenyl 
analogues bearing a 2-amino-2-deoxy-p-o-glucopyranose containing a variety of 
substituents replacing the a-L-rhamnose residue have been designed and synthesized. 
This rhamnose residue is usually found at the 2-0-position of the inner glucose moiety for 
most diosgenyl saponins. Moderate cytotoxic activity is found for most analogues against 
neuroblastoma SK-N-SH cells, breast cancer MCF-7 cells, and cervical cancer Hela 
cells. Mechanistically, diosgenyl saponin analogue A with R = Bz was able to induce cell 
cycle arrest at G1 phase in SK-N-SH cells, while, in contrast, induced cell cycle arrest at 
G2 phase in MCF-7 cells. Disaccharide diosgenyl analogues B bearing an a-L-
rhamnopyranosyl moiety attached to the 4-0H of the 2-amino-2-deoxy-p-o-glucopyranose 
residue containing a variety of substituents at the amino group have also been 
synthesized. The biological investigation of disaccharide analogues B is still underway. 
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1 INTRODUCTION AND OBJECTIVES 
1.1 Saponins 
1.1.1 General saponin features 
Saponins are naturally occurring glycosides that are widely distributed in the plant 
kingdom and lower marine organisms. 1 In recent years, saponins have attracted much 
attention for a host of different biological activities. Saponins are often referred to as 
natural detergents with the name derived from the soapwort plant Saponaria, the root of 
which was historically used to form a soap-like foam. Saponins are also classified as 
phytochemicals and can be found in reasonably high number in numerous food and 
beverage plants.2 Some sources of substantial amounts of saponins include yucca, 
soybeans, garlic, onions, yams, asparagus, quillaja, tea, etc. 3•4 There is also evidence that 
the active constituents in numerous traditional oriental medicines and commercially 
available herbs on the market, such as ginseng, licorice, horse chestnut and red clover 
are saponins. 4•5 The most common commercial source of steroid saponins is from Yucca 
schidigera, while, Quillaja saponaria produces a wide variety of extensively studied 
triterpenoid saponins.6 
1.1.2 Structure and classification of saponins 
Saponins consist of either C-27 or C-30 polycyclic aglycones attached to carbohydrate 
based side chains. The aglycone part, which is also called a sapogenin, is either a steroid 
(C-27) such as hecogenin7 or a triterpenoid (C-30) such as oleanolic acid found in 
oleanane saponins8 (Figure 1 ). The aglycone may contain one or more unsaturated C-C 
bonds. The foaming ability of saponins is caused by the combination of the hydrophobic 
sapogenin and the hydrophilic carbohydrate part. The carbohydrate component consists 
of one or more sugar moieties containing glucose, galactose, xylose, arabinose, 
rhamnose, or glucuronic acid. 6 
1 
hecogenin oleanolic acid 
Figure 1. Structure of typical sapogenins 
Monodesmoside saponins are saponins that have one carbohydrate moiety attached to 
the aglycone, while saponins with two sugar moieties attached to the aglycone at different 
positions, for example, at C-3 and C-26 like in methyl protodioscin, are called 
bidesmoside saponins6 (Figure 2). 
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Figure 2. Monodesmoside balanitin 7 and bidesmoside methyl protodioscin 
The variability of the aglycone structure, the position of sugar moieties on the aglycone 
and the variety of side chains are all factors that contribute to the complexity of saponins. 
Thus, the functionality of saponins has motivated substantial interest in these molecules. 
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As a result of the diversity of structures, steroidal saponins are usually divided into three 
classes, spirostan, furostan, and cholestan saponins, which are, interestingly, 
biosynthetically interrelated.4 
1.1.3 Biological properties of saponins 
Various biological activities have been shown by saponins throughout recent years. 
Commonly, in plants, saponins are found in tissues that are most vulnerable to fungal or 
bacterial attack, or insect predation.6·9 Therefore, one of their roles is to act as a chemical 
barrier or shield in the plant defence system. Some of these saponins act as a means of 
controlling fungus while others act as a defence against insect attack. 9 Furthermore, 
recent research has shown evidence that saponins have potential as a natural insecticide 
against caterpillars Spodoptera /ittoralis and aphids Acyrthosiphon pisum, as various 
saponins have shown growth inhibition against these tested insects. 10 Saponins have also 
been shown to control bacteria in soil. 11 
Numerous studies have demonstrated that saponins are shown to exhibit various effects 
on cholesterol metabolism. Decreased intestinal absorption of cholesterol has been 
exhibited by some saponins 12 while also reducing levels of harmful LDL cholesterol 
selectively in the serum of test subjects including humans. 13'14 The immunostimulatory 
effects of saponins have been noted in several publications in recent years. Quillaja 
saponins have been shown to boost antibody production 15 as well as induce specific 
cytotoxic T-lymphocyte responses. 16 Antiviral activity has been observed in saponins 
purified from Maesa lanceo/ata17 as maesa saponins are capable of deactivating certain 
viruses. 18 Furthermore, saponins have strong antifungal activity against many types of 
fungi. Saponins isolated from Ka/opanax pinctus and the lower leaves of Asparagus 
officina/is have shown high toxicity to fungi through a possible membrane sterol 
interaction. 19·20 Interestingly, it has been found that some saponins have antioxidant or 
reductive properties. The Fabaceae species has given a group of soyasaponins with a 
distinct aglycone component capable of scavenging free radicals. 21 Attached at C-23, the 
2,3-dihydro-2,5-dihydroxy-6-methyi-4H-pyran-4-one (DDMP) moiety reduces superoxides 
3 
to less harmful intermediates therefore reducing cell damage by free radicals. 21 One of the 
most significant findings in recent years has been the cytotoxic activity of saponins on 
numerous cancer cell lines, which will be discussed in further detail in this study. 
1.2 Chemotherapeutic biological background 
1.2.1 The cell cycle 
The cell cycle is the series of events that take place in the cell leading to its replication. 
Immediately after a cell has successfully divided, an intermediate phase called G1 is 
initiated. 22 This gap phase provides additional time for the cell to grow. During the G1 
phase, the cell undergoes an overview of the cellular environment to ensure that the 
conditions are appropriate to support DNA replication. Cells in the G1 phase that have 
received inhibitory signals from other cells or are exposed to extracellular conditions that 
inhibit cell proliferation accumulate in a prolonged non-dividing state called Go. After the 
cell has established the appropriate environment for DNA replication and has reached the 
correct size, it will enter the next phase called the S phase. Synthesis, or S phase, is the 
phase in which DNA is replicated in chromosomes. This phase allows for the replication of 
each cell created by cell division to have identical genetic make-up. Once the process of 
DNA replication has been complete, the cell with duplicated chromosomes enters the G2 
phase. The G2 phase, similar to G1, is a gap phase occurring between the end of DNA 
replication in S phase and before cell division occurs. G2 is the final checkpoint to ensure 
that DNA and other intracellular components have been properly duplicated. Regulatory 
control by important cellular signals and cell growth also occur at this stage before it is 








Figure 3. The cell cycle 
1.2.2 Apoptosis 





Cell proliferation and subsequently cell death are executed in a steady continuous 
process by an array of multiple signalling pathways. For most of the constituents of the 
cell, growth is a steady, continuous process, interrupted only briefly at the M phase, when 
the nucleus, and, consequently, the cell divide in two. Any deregulation or mutation of cell 
cycle components may halt cell death and cause the cells to multiply uncontrollably 
resulting in tumour formation. 24 Nearly all cancers are caused by abnormalities in the 
genetic material of transformed cells. 25 Genetic abnormalities found in cancer activate 
genes which give cells new properties such as protection against programmed cell 
death.26 Thus, interference in the apoptotic capability of a cell leads to the development of 
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cancer in many cases.26·27 However, when a cytotoxic agent is introduced into the 
process, cell proliferation is interrupted and programmed cell death or apoptosis occurs.27 
A portion of the complex apoptosis process is shown in Figure 4. Consequently, cell cycle 
checkpoints and apoptosis play an important part in cancer prevention.23 For example, 
deregulation of the cells' p53 protein, an apoptotic tumour suppressor, results in impaired 
apoptosis activity and, as a consequence, the possible formation of tumours. 28•29 When 
DNA has sustained damage, the p53 gene accumulates to give the cell time to repair by 
preventing cell replication by cell cycle arrest. It can hold the cell in this phase long 
enough to fix damage and thus continue the cell cycle. However, if damage is extensive 
and irreparable, p53 will initiate apoptosis. 30·31 The process of apoptosis is controlled by a 
diverse range of cell signals and pathways but only activation by caspases causes cell 
death.32-35 Caspases are cysteine proteases essential in the role of apoptosis. 32 There are 
two major signalling pathways in apoptosis, with mitochondrial regulation the core of the 
intrinsic pathway and death receptor activation involved in the extrinsic pathway. 36 
Apoptosis in this pathway is controlled by anti-apoptotic Bcl-2 proteins and pro-apoptotic 
Sax and Bak expressions. 34·37'38 When a deregulation of mitochondria occur, cytochrome c 
is released which in turn activates caspase-9.36 This intrinsic pathway is the most 
observed pathway with diosgenyl saponins. Caspase-8 is activated in the direct signal 
transduction pathway or death-receptor extrinsic pathway, of which, along with caspase-9, 








Figure 4. Apoptotic pathways 
1.3 Diosgenyl saponins 
1.3.1 The aglycone - diosgenin 




Of particular interest for anti-cancer studies are the spirostan saponins, and more 
specifically, diosgenyl saponins. Recently, studies on diosgenyl saponins have shown 
growth inhibition by induction of apoptosis in cancer cells. 41 -43 Diosgenin, (25R)-5-




Figure 5. Structure of diosgenin 
Diosgenin is found in several plant species including Trigone/fa foenum graecum, 
commonly called fenugreek44 and the Dioscorea species referred to as yams.45 It is 
obtained by hydrolysis of the glycosidic steroidal saponin form in other species. Since 
being isolated from the Mexican yam Dioscorea mexicana, diosgenin is now an essential 
compound in the pharmaceutical industry as a natural source of steroidal hormones.46 The 
raw material is used for the production of contraceptive steroid drugs such as 
progesterone, and anti-inflammatory steroids, such as cortisone.47 Diosgenin is reported 
to have hypocholesterolemic effects by decreasing cholesterol in serum LDL and 
elevating cholesterol in the HDL fraction. 48-50 Additionally, diosgenin has been investigated 
for possible hypolipidemic and antioxidative effects by upregulating the expression of 
antioxidative enzymes. 51 
1.3.2 Anticancer effects of diosgenin 
In recent years, multiple preclinical studies have demonstrated the anticancer effects of 
diosgenin. Diosgenin has been shown to inhibit the proliferation of HT-29 human colon 
cancer cells and induce apoptotic activity via the intrinsic pathway by modulation of 
caspase-3 and Bcl-2 expressions in vitro. 52 The anti proliferative activity of diosgenin was 
also demonstrated by suppressing fatty acid synthase expression in HER2-
overexpressing breast cancer cells53 and by suppressing 3-hydroxy-3-methylglutaryl CoA 
reductase expression in HCT-116 human colon carcinoma cells. 54 Diosgenin induces cell 
cycle arrest and apoptosis in human leukemia K562 cells with the disruption of Ca2+ 
homeostasis. 55 Varying apoptotic mechanisms have been observed as induction through 
G2/M cell cycle arrest and p53-independent p21 up-regulation occurred in He La cells. 
56 
8 
The proapoptotic mechanism of diosgenin also involved the activation of caspase-3 in 
Hela cells. 57·58 The antiproliferative effects of diosgenin were demonstrated through the 
p53-dependent apoptotic mechanism in melanoma M4Beu cells and laryngocarcinoma 
HEp-2 cells. 59 In addition, diosgenin arrested myelogenous leukemia KBM-5 cells at the 
sub-G1 phase of the cell cycle. 5° Other investigators have reported diosgenin to initiate 
cell cycle arrest in G1 phase and apoptosis in the human osteosarcoma 1547 cell line by 
increasing the tumour suppressing p53 expression. 51 Further, its proapoptotic activity was 
found to be greater than that of two structurally similar plant steroids, hecogenin (Figure 1) 
and tigogenin. 62 
1.3.3 Structure function activity of diosgenin 
The ability of diosgenin to alter cell cycle arrest and induce apoptosis has accordingly 
inspired considerable interest for structure function studies. Trouillas eta/. have compared 
eight plant steroids with structural similarities to diosgenin for their biological activity 
against human 1547 osteosarcoma cells. 53 In the study, they chose to investigate the 
apoptotic activity, proliferation rate, and cell cycle distribution on human 1547 
osteosarcoma cells. The other objective was to establish structural criteria as related to 
molecular activity. The structural characteristics focused on were: the 5,6-double bond, 
the configuration at C-25, and the role of the osidic bond. 
Importance of stereoisomerism at C-25 
I 
H 
Importance of the 5,6-double bond 
Figure 6. Structure function attributes of diosgenin 
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The key results of the study demonstrate that biological activity is attributed to the 
presence of the 5,6-double bond and the S stereochemistry at C-25 on the androst-5-en-
3-ol skeleton (Figure 6).63 These two important structural features are present in diosgenin 
and their presence is essential for compounds to exhibit strong apoptosis and cell cycle 
arrest. 
1.3.4 Properties of diosgenyl saponins 
Diosgenyl saponins are the most abundant steroidal saponins in nature. These saponins 
have been shown to exhibit a wide variety of biological activities including 
cardiovascular, 54 antifungal, 65 and antibacterial activities. 56 A common property of several 
diosgenyl saponins is their ability to inhibit the growth of cancer cells. 61 •67•68 The structural 
diversity of diosgenyl saponins lies in the sugar moiety. The structure of diosgenyl 





Figure 7. Structure of trillin 
Having a single glucose sugar attached via the 3-0-position on the aglycone diosgenin, it 
is the simplest diosgenyl saponin. Some of the more common saponins belonging to this 
group are ophiopogonin C', dioscin, and polyphyllin D (Figure 8). 
10 
ophiopogon in C' 
Figure 8. Diosgenyl saponins 
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The structure of most diosgenyl saponins usually has an L-rhamnopyranose moiety 
attached to the 2-0-position and another sugar moiety at the 3-0- or 4-0-position. In one 
study, trillin has been shown to have no significant cytotoxic activity (IC50 > 20 J.!M) against 
HL-60 human leukemia cells, however, when an a-L-rhamnopyranosyl sugar is attached 
at C-2 of the glucopyranosyl moiety, ophiopogonin C' is formed, and significant cytotoxic 
activity appears (ICso = 1.8 J.!M). 70 Polyphyllin D, isolated from the Paris polyphy/la 
species, has been shown to promote some cardiovascular and cytotoxic activities (IC50 = 
0.5-7.0 J.!M). 71 -75 Polyphyllin D has been shown to be cytotoxic and induce apoptosis in the 
hepatocellular carcinoma HepG2 (IC50 = 7.0 J.!M), and the drug resistance R-HepG2 cell 
lines (IC50 = 5.0 J.!M).41 Mechanistically, it was found that polyphyllin D initiated apoptotic 
activity via mitochondrial fragmentation. 74 In MCF-7 breast cancer cells, polyphyllin D 
inhibited growth with an ICso value of 5.0 J.!M. It induced a down-regulation of the anti-
apoptotic Bcl-2 expression and activated the caspase-9 expression suggesting that 
polyphyllin D elicits apoptosis through mitochondria dysfunction in these cells. 75 
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1.3.5 Dioscin 
Another one of the most promising diosgenyl saponins has been dioscin. Dioscin exists 
widely in the plant kingdom and has been a major component in many traditional Chinese 
herb medicines. Structurally, dioscin starts with a ~-o-glucopyranosyl unit attached at the 
3-0H of diosgenin and extends with two a-L-rhamnopyranosyl residues at the 2-0- and 4-
0-positions of the glucose moiety (Figure 8). Dioscin has been shown to be one of the 
most potent diosgenyl saponins with a range of cytotoxicity (IC50 = 0.5-3.8 )lM) in various 
cancer cell lines.68 Cai eta/. have demonstrated the induction of apoptosis in the sub-G 1 
phase in Hela cells by dioscin.76 Low activity of caspase-8 indicated that the death-
receptor pathway was not activated, whereas high activity of caspase-9 was shown 
suggesting involvement of mitochondria. In addition, a down-regulation of the anti-
apoptotic Bcl-2 expression was detected further confirming the mitochondrial pathway. 
The intrinsic mitochondrial pathway was also revealed by dioscin action on human 
myeloblast leukemia HL-60 cells. 41 The activation of caspase-9 and, subsequently, 
caspase-3 with a deregulation of the Bcl-2 protein confirms this pathway. 
1.3.6 Structure activity relationships of dioscin 
Recently, some structure-activity studies have been presented with dioscin. In one study,77 
all eight mono-methylated dioscin derivatives were synthesized and their cytotoxicity was 
observed. The tumour inhibitory activities of all eight were tested against lymphocytic 
leukemia P388 and alveolar basal epithelial A549 cell lines and it was observed that the 
inhibitory activity was retained when the 6-0H of the glucopyranosyl moiety and the 4-0H 
of the rhamnopyranose attached at the 4-0-position on the glucopyranosyl moiety were 
methylated.77 The results show that the other six of the eight hydroxyls on dioscin might 
be key for antitumour activity. As a result, 6'-N-acyl-and 6'-0-acyl-dioscin derivatives were 
prepared in hopes of improving the antitumour activity of dioscin. 78•79 Interestingly, results 
from both studies indicate that all analogues were largely inactive. The importance of the 
1 ,2-trans ~-glycosidic bond in dioscin is proven by Miyashita eta/. as they have prepared 
both a- and ~-chacotriosyl glycosides and compared their activity. 80 The results show that 
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in cytotoxicity tests with A549 and HepG2 cell lines, the p-glycosides show superior 
growth inhibition over their a-glycoside counterparts. 
1.4 Objectives of the present work 
Structural similarity is a problem that arises from the extraction of saponins in one specific 
plant species.4 The distinct morphology of saponins calls for tedious and exhaustive 
techniques for isolation, structure clarification, and biological testing. As a result, many 
saponin extracts from herbs have been used directly, without pharmacological 
assessment, to treat various human diseases. Therefore, isolation of a substantial amount 
of a single pure saponin would be of considerable interest. Chemical synthesis of 
diosgenyl saponin analogues would provide a realistic way to obtain homogeneous 
saponins. The variability of the aglycone structure, the position of attachment of moieties 
on the aglycone and the variety of the side chains are all factors that contribute to the 
complexity of a structure activity relationship study (SAR).68 In this study, it is intended to 
synthesize a catalogue of diosgenyl saponin analogues to study their cytotoxic effects 
against cancer cells. In addition, the mechanism of their anticancer activity will be 
investigated. 
1.4.1 Monosaccharide diosgenyl saponin analogues 
There has been evidence that less complex diosgenyl saponins like ophiopogonin C'70 
and analogues synthesized by Myszka eta/. 81 have proven to exhibit cytotoxic activity. 
The main structural features for activity include a ~-linked carbohydrate moiety at C-3 of 
the steroidal aglycone and modification at C-2 of the sugar residue. Myszka et a/.81 
reported the apoptosis-inducing property in B cell chronic leukemia cells by synthetic 
diosgenyl 2-amino-2-deoxy-p-o-glucopyranoside hydrochloride and one urea derivative in 
combination with cladribine (2-CdA). These findings, along with the strong cytotoxicity of 
ophiopogonin C', 70 indicate that diosgenyl saponin analogues carrying only one or two 
sugar residues might show good antitumour potential. However, limited studies into the 
structure activity relationship have been carried forward. Therefore, one aspect of the 
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thesis is to synthesize simpler diosgenyl saponin analogues (Figure 9) for biological 
evaluation and structure activity relationship studies. In addition, one dimeric diosgenyl 















Figure 9. Monosaccharide diosgenyl saponin analogues 
1.4.2 Disaccharide diosgenyl saponin analogues 
Diosgenyl saponins isolated from various extracts of plants have showed cytotoxicity 
against a variety of cancer cell lines. 61 •67·68'76 Activity of diosgenyl saponins has been 
shown to increase when the 4-0H of the glucopyranosyl moiety is rhamnosylated as 
shown by the activity of dioscin. 70 Thus, a set of disaccharide diosgenyl saponin 
analogues designed from more structurally complicated molecules like dioscin were 




HO I R 
HO 
disaccharide diosgenyl saponin analogues 
Figure 10. Disaccharide diosgenyl saponin analogues 
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2 RESULTS AND DISCUSSION 
2.1 Monomeric diosgenyl saponin analogues 
2.1.1 Design of monomeric diosgenyl saponin analogues 
As mentioned, diosgenyl saponins have shown growth inhibition against a variety of 
cancer celllines. 61 '67'68'76 Since rhamnose attachment at C-2 of the inner sugar moiety 
results in increased activity, modification at C-2 is a viable option for synthesis of 
diosgenyl saponin analogues. Thus, a synthetic strategy towards simpler structural 
analogues was initiated (Scheme 1 ). A selection of functional groups were incorporated: 
an acetyl group, benzoyl providing an aromatic moiety, succinic anhydride as an acid 






Scheme 1. Monomeric diosgenyl saponin analogues 
R = Ac 
R = Bz 





2.1.2 Synthetic strategy for monomeric diosgenyl saponin analogues 
A strategy of employing the efficient 2,2,2-trichloroethoxycarbonyl (Troc) amine protection 
group for 2-deoxy sugars was implemented. The reactive nucleophilic amine was N-
protected by the Troc group which is part of an orthogonal set of protecting groups that 
can be cleaved under reductive p-elimination conditions.82 This establishes the crucial N-
Troc group which possesses effective participating group properties for the formation of 
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stereospecific ~-glycosides.83 '84 Therefore, the monosaccharide diosgenyl saponin 
analogue structure with a variety of R groups was chosen as the target molecule for the 
synthesis of diosgenyl saponin analogues (Scheme 2). Acylating agents were chosen for 
coupling to the deprotected amino group on intermediate I. Accordingly, the aglycone 
chosen was commercially available diosgenin and the carbohydrate moiety is the suitably 














monosaccharide diosgenyl saponin analogues 
Ac = acetyl (CH3CO) 
Troc = trichloroethoxycarbonyl (CI3CCH20CO) 
HO diosgenin 
Scheme 2. Retrosynthetic analysis for monomeric diosgenyl saponin analogues 
2.1.3 Synthesis of the glycosyl trichloroacetimidate donor 1 
According to known literature procedures, protected glycosyl imidate 184 was prepared as 















CI3C/""-.. 0~ 0 
j H2NN 2HOAc, DMF 50°C, 81% 
Scheme 3. Synthesis of the glycosyl imidate 
2.1.4 Synthesis of ~-glycoside 4 
The glycosylation with 2-N-Troc group donors usually affords 1 ,2-trans-glycosides 
stereoselectively by virtue of neighbouring group participation. 83·84 Synthesis of P-
glycoside formation in saponins has been demonstrated efficiently by Deng eta/. 85 
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Therefore, glycosylation was achieved between 1 and diosgenin 2 (Scheme 4) under 
promotion by the catalyst trimethylsilyl trifluoromethanesulfonate (TMSOTf) in 





J TMSOTf, CH,C:'· O"C, 98% 
J Zn dust HOAc, rt, 96% 
Scheme 4. Glycosylation with the steroidal acceptor and synthesis of amine intermediate 
The 1H NMR data of 3 (8 4.80, d, J = 8.0 Hz)84 confirmed the existence of the 1,2-trans p-
linkage by the coupling constant of the anomeric proton. Compound 3 is then treated with 
zinc in acetic acid to provide free amine 4 in 96% yield as the main intermediate for 
subsequent amide bond synthesis. 
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2.1.5 Synthesis of the diosgenyl monosaccharide analogue series 
Treatment of 4 with acetic anhydride (Ac20) in pyridine gave 5 in 92%, with benzoyl 
chloride (BzCI) in pyridine gave 6 in 84% yield, and with succinic anhydride in pyridine 











succinic anhydride, pyridine, 
rt, 73% 
7 
Scheme 5. Coupling of amine with various acylating reagents 
The coupling reaction between 4 and N-acetyi-L-alanine (AcHN-L-Aia-OH) resulted in 
almost complete racemization of the alanine residue when N,N'-diisopropylcarbodiimide 
(DIC) is used as the condensation agent (Scheme 6). The so-formed diastereomeric 
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mixture 8a/8b is chromatographically inseparable, but readily recognized on its 1 H NMR 
spectrum (8 4.84, d, J = 8.5 Hz for the anomeric proton of the sugar residue in L-alanine-




DIC, DCM, rt 
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AcHN-L-Aia-OH, HBTU, Lipoic acid, HBTU, DIPEA, 
DIPEA, DMF, rt, 78% DMF, rt, 83% 
OAc 
Aco~O-





Scheme 6. Coupling of the amine with N-acetyi-L-alanine and (±)-a-lipoic acid 
This racemization can be largely suppressed (<5%) when 2-(1H-benzotriazole-1-yl)-
1, 1 ,3,3-tetramethylaminium hexafluorophosphate (HBTU) is employed as the activating 
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agent. As a result, 4 was coupled to AcHN-L-Ala-OH by HBTU with N,N-
diisopropylethylamine (DlPEA) in dry DMF to give Sa in 78% yield. Under the same 
conditions, (±)-a-lipoic acid was coupled to 4 to give 9 in 83% yield. The final removal of 
the acetyl groups in 5-9 by treatment with sodium methoxide in dichloromethane-methanol 
affords the corresponding diosgenyl saponin analogues 10-14, respectively (Scheme 7). 







NaOMe, MeOH/DCM, rt 
5 R =Ac 
6 R = Bz 
yH3 
8 R = AcH~CO 
~~ 
HvH~O 




9 R =I I 
s-s 
14 R =I I 
s-s 
Scheme 7. Deprotection to target monomeric diosgenyl saponin analogues 
2.2 Dimeric diosgenyl saponin analogue 
2.2.1 Design of dimeric diosgenyl saponin analogue 
Many biological systems interact through multiple, simultaneous molecular contacts, and, 
in the recent past the design of multivalent ligands and inhibitors has become a focus of 
inquiry in molecular biochemistry and drug discovery. 86 As a result, one dimeric diosgenyl 
saponin analogue was prepared in hopes of improving the antitumour activity of the 
monomeric analogue. 
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2.2.2 Synthetic strategy for dimeric diosgenyl saponin analogue 
The strategy employed for the dimeric diosgenyl saponin analogue (Scheme 8) was to 
use the key synthesized amine intermediate 4 connected via a linker molecule. Thus, the 
















0 A cO~ 
NH2 
dimeric diosgenyl saponin analogue 
4 
Scheme 8. Retrosynthetic analysis for dimeric diosgenyl saponin analogue 
2.2.3 Synthesis of dimeric diosgenyl saponin analogue 
The reaction of two equivalents of amine 4 with one equivalent of the dicarboxylic acid, 
adipic acid, in the presence of HBTU as the activating agent, gives the desired dimer 16 in 
56% yield, together with 21% of the monomeric product 15. Compounds 15 and 16 are 
treated with sodium methoxide to give saponin analogues 17, in quantitative yield, and 18, 
22 








15 R =Ac~ 
NaOMe, MeOH/DCM (1:1), 100% 
17 R = H 
0 
H~OH 
0 adipic acid 








NaOMe, MeOH/DCM (1:1), 98% 
18 R = H 
Scheme 9. Synthesis of diosgenyl saponin dimer 
2.3 Disaccharide diosgenyl saponin analogues 
2.3.1 Design of disaccharide diosgenyl saponin analogues 
Dioscin, isolated from various extracts of plants, has shown cytotoxicity against multiple 
cancer cell lines.41 '76·77 Structurally, ~-o-glucopyranose is attached to the 3-0H group of 
the aglycone diosgenin, and a-L-rhamnopyranose is attached to the 2-0- and 4-0-
positions. Encouraged by the synthesis of our monosaccharide saponin analogues and 
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previous SAR studies70 , a set of disaccharide diosgenyl saponin analogues with a dioscin-
like backbone were chosen as target molecules for the synthesis (Scheme 1 0). A variety 
of acylating reagents were selected to replace the a-L-rhamnose found at the 2-0-position 
on dioscin and various other diosgenyl saponins. Benzoyl and lipoic acid functionalities 
were chosen for direct comparison in biological activity to the monosaccharide analogues. 
In addition, two aromatic nitro groups were integrated as they are involved in redox 






Scheme 10. Disaccharide diosgenyl saponin analogues 









2.3.2 Synthetic strategies for disaccharide diosgenyl saponin analogues 
From a strategic standpoint, two differing reaction pathways are evident with 
oligosaccharide saponin synthesis (Scheme 11 ). 88 Fabrication of a separate sugar moiety 
followed by subsequent glycosylation with an aglycone presents a convergent synthetic 
strategy. This strategy is advantageous as the sugar moiety can be manipulated without 
the aglycone present. Whereas, attaching sugar moieties sequentially to a glycoside 
complex can be perceived as synthesis in a linear fashion. The second strategy generally 
benefits stereospecific and high yielding glycosidic bond formations. Both strategies have 
thus been explored as alternate pathways in this work to provide a complete illustration of 
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saponin analogue synthesis. 
Conve'!Jent sbateg1 
1. FG manipulation 
2. glycosylation 
1. FG manipulation 
2. glycosylation 
Scheme 11. Two main strategies for saponin synthesis 
2.3.3 Convergent synthesis strategy for disaccharide diosgenyl analogues 
Following a convergent type strategy, disaccharide diosgenyl saponin analogues with a 
variety of R groups were chosen as target molecules for the synthesis (Scheme 12). 
Acylating agents were chosen for coupling to the deprotected amino group on 
intermediate Ill, while the aglycone is diosgenin. The carbohydrate moiety is a 
disaccharide, IV, composed of two sugar residues: the 2-amino-2-deoxy-o-glucopyranose 
connected via a ~-glycosidic linkage to the aglycone and an L-rhamnopyranose moiety 
connected via an a-linkage at the 4-0-position. 
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AcO OAc Ill n 
~~ 
Ac~ TrocHNOC(NH)CCI, HO 
AcO OAc IV 
diosgenin 
0-glucosamine + L-rhamnose 
Ac = acetyl (CH 3CO) 
Bz = benzoyl (C6H5CO) 
Troc = trichloroethoxycarbonyl (CI3CCH20CO) 
Scheme 12. Retrosynthetic analysis for disaccharide diosgenyl saponin analogues 
2.3.3.1 Selective benzoylation of glucosamine derivative 19 
The key sugar of the disaccharide is the 2-amino-2-deoxy-glucopyranose, protected at 2-
NH and rhamnosylated at 4-0H. The relative reactivity of hydroxyl groups in D-
glucopyranose was estimated to be 6-0H>>3-0H=::1-0H>2-0H>4-0H.89 We hoped that 
similar reactivity could be observed in glucosamine derivative 1990 so that selective 
benzoylation might lead to the formation of 1 ,3,6-tri-0-benzoylated 22 as the major 
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product. With its 4-0H free, 22 could serve as the proper glycosylation acceptor for the 
preparation of disaccharide intermediate IV (Scheme 12). Therefore, the known 2-deoxy-
glucopyranosyl derivative 1990 was treated with 3.1 equivalents of benzoyl chloride (BzCI) 
and catalytic dimethylaminopyridine (DMAP) at -40 oc in a pyridine-dichloromethane 
mixture (1.5 : 1 ). The 3,6-di-0-benzoylated product 20 was obtained in 23% yield, the 
3,4,6-tri-0-benzoylated product 21 in 27% yield, and the 1 ,3,4,6-tetra-0-benzoylated 
























As 1 ,3,6-tri-0-benzoylated 22 was not formed, Scheme 14 shows a possible conformation 
which explains 4-0H benzoylation over 1-0H. The anomeric hydroxyl group stabilizes the 
sugar in a 5-member ring formation. Intramolecular hydrogen bonding from the anomeric 
hydroxyl and the N-H group form this system. The hydrogen bonding decreases electron 
density on the oxygen and as a result nucleophilicity decreases. Further investigation is 
needed to provide evidence for the existence of such intramolecular hydrogen bonding. 
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Scheme 14. Possible intramolecular hydrogen bonding interaction in derivative 20 
Since the observed reactivity of glucosamine derivative 19 was shown to be 6-0H>>3-
0H>4-0H>1-0H, it was decided that compound 20 could be used as the acceptor. 
Therefore, glucosamine derivative 19 was treated with 2.1 equivalents of benzoyl chloride 
and catalytic DMAP at -40 oc in a pyridine-dichloromethane mixture (1.5: 1) to yield the 
desired 3,6-di-0-benzoylated product 20 in 72% yield and 3,4,6-tri-0-benzoylated 21 in 
14% yield as mostly the a isomers (Scheme 15). The 1H NMR spectrum of 21 shows a 
signal at 8 = 5.72 (dd, J = 9.5, 10.0 Hz) demonstrating the existence of 4-0H benzoylation 















Scheme 15. Selective benzoylation of glucosamine derivative 
28 
2.3.3.2 Synthesis of disaccharide glycosyl imidate 27 
Glycosylation of the readily available rhamnopyranosyl donor 2391 with 20 in the presence 
of TMSOTf as the catalyst at -20 oc in dichloromethane gave the desired 4-0-
rhamnosylated disaccharide 24 in 71% yield (Scheme 16). The rhamnose connection was 
ascertained by 1H NMR data as a broad singlet is observed at 8 = 5.36 ppm. Observation 
of a di-rhamnopyranosyl trisaccharide 25 from a crude 1H NMR spectrum was observed in 
approximately 15% yield but an analytically pure product was not obtained. 








TMSOTf, DCM, -20oC 
15% 
OAc 24 ~rt 
1 
OBz 
CI3CCN, DBU, rt ~
0 Bz ..-r-- ~ Jsz~rocH NoAc 
80% Ac~ 
BzO AcO OAc 26 86% 
TrocHNOC(NH)CCI3 
OAc 27 
Scheme 16. Synthesis of disaccharide 
Compound 24 was readily transformed into acetate derivative 26 by acetic anhydride in 
pyridine. The coupling constant of the 1H NMR spectrum (8 6.24, d, J = 3.5 Hz) confirmed 
that the anomeric position was acetylated, and that this glycosylation occurred at 4-0H. 
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lmidate formation was achieved within 20 min by addition of trichloroacetonitrile in the 
presence of 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as base to provide the 
disaccharide trichloroacetimidate donor 27 in 80% yield. Longer reaction times in this 
reaction lead to decreasing yield as additional spots on TLC were observed. To further 
confirm that the anomeric position was indeed modified, 1H NMR data of the anomeric 
proton of 27 (8 6.42, d, J = 3.5 Hz) confirmed the existence of the a-imidate. 
2.3.3.3 Glycosylation of disaccharide moiety 27 with the aglycone 
Glycosylation of disaccharide donor 27 with diosgenin in the presence of TMSOTf as the 
catalyst in dichloromethane at room temperature gave the desired steroidal glycoside 28 
in 80% yield (Scheme 17). The signals of two anomeric carbons were found at 98.89 and 
99.88 ppm in its 13C NMR spectrum, while the presence of the 1 ,2-trans ~-glycosidic 
linkage was verified by the observation of a 1H doublet at 8 = 4.77 (J = 8.0 Hz) in the 1H 
NMR spectrum. 




---r--o--) z TrocHN 
c~ 28 
AcO OAc 
Scheme 17. Glycosylation of disaccharide donor 
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Although the yield was good for this convergent synthetic strategy, product 20 in Scheme 
15 and product 24 in Scheme 16 exist as a/p mixtures and therefore have presented 
challenges in chromatographic separations. The alternate linear pathway was thus 
investigated, as intermediate 3 from the previous monomeric diosgenyl saponin analogue 
synthesis was readily available. 
2.3.4 Linear synthesis strategy of disaccharide diosgenyl saponin analogues 
OH 
o~o 
HO~ RNH disaccharide diosgenyl saponin analogues 
HO OH 
OBz 









Ac = acetyl (CH 3CO) 
Bz = benzoyl (C6H5CO) 
Troc = trichloroethoxycarbonyl (CI3CCH20CO) 
Scheme 18. Linear synthesis strategy for disaccharide analogues 
The observed reactivity of glucosamine derivative 19 was shown to be 6-0H>>3-0H>4-
0H>1-0H and a 3,6-di-benzoylated product 20 was shown to be readily formed. 
As an alternative pathway for synthesizing disaccharide diosgenyl saponin analogues, the 
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linear tactic was chosen to reach the target molecules (Scheme 18). Suitably protected 
rhamnose donor 23 was attached to the partially protected acceptor V made from the 
previously synthesized intermediate 3. 
2.3.4.1 Synthesis of diosgenyl glycosyl acceptor 30 
The previously synthesized diosgenyl 3,4,6-tri-0-acetyl-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamino )-P-0-glucopyranoside 3 is the intermediate for the synthesis 
of the diosgenyl glycosyl acceptor (Scheme 19). Initially, intermediate 3 was treated with 
sodium methoxide (NaOMe) in a methanol-dichloromethane mixture for subsequent acetyl 
group removal. However, selective 0-deacetylation leaving the N-Troc group intact was 
unsuccessful as additional spots on TLC were observed. The 1H NMR data of the crude 
product suggested that the corresponding methyl carbamate 29b was formed as the side 
product. This carbamate was eventually formed as the major product when the reaction 
was extended long enough. Further investigation led to the guanidine/guanidinium nitrate 
method92 for mild and selective 0-deactylation which leaves the N-Troc group intact. 
Thus, intermediate 3 was treated with a stock solution composed of guanidinium nitrate 
and NaOMe in a methanol-dichloromethane mixture (9 : 1) affording the deacetylated 
glucopyranoside 29a in 90% yield. Selective benzoylation of 29a was achieved with 2.1 
equivalents of BzCI and catalytic OMAP at -40 oc in a pyridine-dichloromethane mixture 
(1.5: 1) to give the 3,6-di-0-benzoylated 30 in 69% yield. The tri-0-benzoylated product 
31 was formed in approximately 11% yield, but an analytically pure product was not 
obtained. Precautionary action of freeze drying 29a in dioxane had to be implemented to 
remove all methanol from the previous reaction step as methyl benzoate is readily formed. 
Consumption of benzoyl chloride by residual methanol interfered with the portion size of 
benzoyl chloride added in this selective reaction. Thus, the reaction was carefully monitored 
by TLC and the quantity of benzoyl chloride was adjusted accordingly. Additionally, the 3-
0- and 6-0-sites of benzoylation were proven with 1 H-1 H COSY 20 NMR spectroscopy, 
as both the 3-0- and 4-0-benzoylated protons can give a double doublet splitting pattern 








NaOMe, DCM/MeOH (1:1), rt 










Scheme 19. Synthesis of the diosgenyl glycosyl acceptor 
2.3.4.2 Glycosylation of diosgenyl glycosyl acceptor 30 
29b 
Glycosylation of rhamnopyranosyl donor 23 with acceptor 30 in the presence of TMSOTf 
as the catalyst in dichloromethane at room temperature gave the desired steroidal 
glycoside 28 in 94% yield (Scheme 20). The 1H NMR and 13C NMR spectra of the 
samples of 28 obtained from both synthetic pathways were indistinguishable indicating 
that the products of the two sequences were identical. 
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~C(NH)CCI, 
Ac AcO OAc + HB~O 
23 TrocHN 30 
j TMSOTf, DCM, rt, 94% 
Scheme 20. Glycosylation of diosgenyl glycosyl acceptor 
2.3.5 Synthesis of the disaccharide diosgenyl analogue series 
Arriving at the same diosgenyl disaccharide intermediate 28 through both pathways, a 
variety of functional groups can now be added for structure activity relationship studies. 
Removal of the amino protecting Troc group on the 2-deoxy-2-aminosugar moiety of 28 
was achieved under ~-elimination conditions by treatment with zinc dust in acetic acid to 
afford 32 in 96% yield. Benzoyl chloride was coupled to 32 in pyridine at room 
temperature to give 33 in 80% yield. Lipoic acid was coupled to 32 by HBTU with catalytic 
DIPEA in dry DMF to give 34 in 83% yield. Compound 32 was treated with 3-nitrobenzoic 
acid in the presence of HBTU and catalytic DIPEA in dry DMF to yield 35 in 83% yield and 
in the same way 3,5-dinitrobenzoic acid was added to 32 under similar conditions to yield 
36 in 76% yield (Scheme 21 ). 
34 
OAc 
3,5-dinitrobenzoic acid, HBTU, 





3-nitrobenzoic acid, HBTU, 36 ~ -/; N02 
DMF, rt, 83% 







Scheme 21. Coupling of diosgenyl disaccharide with various acylating reagents 
Finally, compounds 33-36 were subjected to deprotection with NaOMe in a methanol-
dichloromethane mixture (2 : 1) to afford target analogues 37-40 in excellent yield 
(Scheme 22). 
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91% 
Scheme 22. Deprotection to target diosgenyl disaccharide analogues 
2.4 Biological evaluation 
96% 
All diosgenyl saponin analogues are new compounds with the exception of compound 10. 
The synthesis of compound 1 0 was reported earlier, 81 but no biological activity has yet 
been described for this compound. The cytotoxicity of monosaccharide analogues 10-14, 
17 and 18 have been tested against several human cancer cell lines by Dr. Mary Lynn 
Tassotto and Dr. John Th'ng at the Thunder Bay Regional Health Sciences Centre and the 
results are described below (Table 1 ). Cell lines included in testing are SK-N-SH 
neuroblastoma, MCF-7 breast cancer, and Hela cervical cancer cell lines. The rapid 
assay employed was the MTT method that measures cell viability, according to the 
method described by Carmichael et a/. 93 
36 
Compound 
Table 1. In vitro cytotoxic activity (IC50, ~-tM) of diosgenyl saponin analogues 
The inhibitory concentration (ICso) is the concentration that inhibits the growth of cells by 
50% when compared to untreated cells. The IC5o results represent the average ICso ±SO 
value obtained from a minimum of n = 2 independent MTT assays for each compound. As 
a control, the MCF-7 cells were treated with the chemotherapeutic agent Doxorubicin. 
2.4.1 Inhibition effect, anticancer activity, and SAR 
The structure activity relationship studies on diosgenyl saponins have been hampered by 
the availability of homogeneous saponins. The success of the chemical syntheses in this 
thesis presents an opportunity to investigate the SAR of these molecules. The most 
significant finding is that modification at the 2-N-position of the glycosyl moiety alters 
growth inhibition and shows some insight into the mechanism of antitumour activity. The 
inhibitory activity was observed to vary from 4.8 ~-tM to greater than 20 f.!M for the 
monosaccharide analogues against all three cell lines. The compound that exhibits the 
greatest cytotoxicity was analogue 14 with a lipoic acid residue attached showing an IC5o 
value ranging from 4.8-7.3 ~-tM against all three cell lines. Lipoic acid is an antioxidant that 
can be readily reduced to its open chain dihydrolipoic acid94 and has been reported to 
exhibit antiproliferative action against WM35 and A350 melanoma cells.95 The disulfide 
bond and redox property of compound 14 in relation to the anticancer action is worth 
further investigation. The dimeric analogue 18 shows the lowest cytotoxicity with an ICso;::: 
19.2 ~-tM and is noticeably less active then its monomer 17 (ICso ;::: 11.3 ~-tM) against all 
37 
three cell lines. The Hela cervical cancer cells seem to be the most resistant to all the 
compounds with the exception of compound 12. Compounds 13 and 17 are most active 
against MCF-7 breast cancer cells when compared to the other two cell lines. Compound 
17 having an additional CzH4 in the side chain relative to 12, is more active in MCF-7 cells 
(ICso = 22.0 ~-tM for 12 and IC5o = 11.3 ~-tM for 17) but, interestingly, their activity is 
reversed against Hela cells (IC50 = 13.9 ~-tM for 12 and IC50 > 20.0 ~-tM for 17). The 
detailed antitumour mechanism of the action of diosgenyl saponins still remains unclear. 
However, some insight has been detailed in the study herein. Compound 11 induces cell 
cycle arrest at G1 phase in SK-N-SH neuroblastoma cells while in MCF-7 breast cancer 
cells it induces cell cycle arrest at Gz phase (data not shown). The cell cycle arrest at 
different phases suggests cell death involves a different action mechanism against cancer 
cell lines from different tissue origins. 
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3 CONCLUSION 
Saponins are natural occurring glycosides that are widely distributed in the plant kingdom 
and lower marine organisms. Diosgenyl saponins are among the most abundant steroidal 
saponins and possess a variety of biological activities, the most significant being the 
demonstration of anticancer activity through apoptosis in a variety of cancer cell lines. The 
chemical synthesis presented provides homogeneous diosgenyl saponins affording 
opportunities for understanding them and their anticancer mechanism of action. A set of 
mono- and disaccharide diosgenyl saponin analogues have thus been synthesized and 
the biological activity of the monosaccharide analogues has been tested. 
Key structural features achieved for the monosaccharide analogue synthesis include the 
1 ,2-trans-~-linkage at C-3 and the modification at C-2 of the glucosyl unit. A glycosyl 
donor possessing a neighbouring participating Troc group was used for the construction 
of a 1 ,2-trans-~-glycosidic linkage, the natural linkage in diosgenyl saponins, in a 
stereocontrolled manner. A TMSOTf glycosylation method has been successfully applied, 
utilizing the imidate protocol, which required only a catalytic amount of the Lewis acid for 
promotion under mild conditions. Various acyl substituents were successfully introduced 
at the 2-deoxy-2-amino of the sugar moiety, and, additionally one dimer was synthesized. 
The monosaccharide analogues 10-14, 17 and 18 synthesized herein were indeed 
biologically active showing moderate cytotoxicity for most compounds. The most active 
being analogue 14 with a lipoic acid residue attached showing a ICso value ranging from 
4.8-7.3 ~M. Different mechanisms of action were also exhibited as diosgenyl saponin 
analogue 11 was able to induce cell cycle arrest at G1 phase in SK-N-SH cells, while, 
inducing cell cycle arrest at G2 phase in MCF-7 cells. 
A convergent strategy was employed for the synthesis of the disaccharide diosgenyl 
saponin analogues. Starting with glucosamine derivative 19, it was found during selective 
benzoylation that the reactivity of the derivative was 6-0H>>3-0H>4-0H>1-0H. As a 
result, di-0-benzoylated 20 was synthesized as the glycosyl acceptor for the glycosylation 
of the a-L-rhamnose imidate 23 at the key 4-0-position using the TMSOTf protocol. This 
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was followed by subsequent glycosylation with diosgenin using the same TMSOTf method 
to yield intermediate 28. Difficulties in chromatographic separation led to the more 
straightforward linear synthesis, in which the previously synthesized 3 was deprotected 
and then di-0-benzoylated to produce 30. With 4-0H open, glycosylation witha-L-
rhamnose moiety 23 was achieved to yield intermediate 28. The amino group on 28 was 
deprotected and four different acylating agents were attached. Benzoyl and lipoic acid 
residues were attached for comparison to the monosaccharide analogues and two 
aromatic nitro groups were incorporated. The biological activity of the disaccharide 
diosgenyl saponin analogues is still under investigation. 
In conclusion, the chemical syntheses presented have provided a better understanding of 
the structure activity relationships of diosgenyl saponins. The successful synthesis of new 
diosgenyl saponins and the development of the method provided can be used to easily 
modify or build a saponin library. With promising results from some of the compounds, it is 
of hope that the information presented will lead to the discovery of a clinically useful 
synthetic diosgenyl saponin. 
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4 EXPERIMENTAL 
4.1 General methods 
All air and moisture sensitive reactions were performed under nitrogen atmosphere. All 
commercial reagents were used as supplied. Pyridine was distilled over potassium 
hydroxide, dichloromethane was distilled over calcium hydride, and methanol was distilled 
from magnesium turnings and a catalytic amount of iodine. Anhydrous N,N-
dimethylformamide (DMF) was purchased from Aldrich. ACS grade solvents were 
purchased from Fisher and used for chromatography without distillation. TLC was 
performed on Silica Gel 60A F2s4 (thickness 250 J..Lm) purchased from Silicycle Inc., 
Canada, with detection by fluorescence (254 nm) and by dipping into 15% H2S04 solution 
and/or Mostaine reagent [ammonium molybdate (NH4)6Mo70 24-4H20 (20 g) and Cerium 
(IV) sulfate Ce(S04)2·xH20 (0.4 g) in 10% H2S04 solution (400 ml)] followed by charring at 
-120 °C. Flash column chromatography was performed on Silica Gel60 (40-63 !Jm) also 
purchased from Silicycle Inc., Canada. 1H and 13C NMR spectra were recorded on a 
Varian Unity lnova 500 MHz spectrometer. Tetramethylsilane (TMS, 8 0.00 ppm) or 
solvent peaks were used as internal standards for 1H and 13C NMR spectra. The chemical 
shifts were given in ppm and coupling constants in Hz indicated to a resolution of± 0.5 
Hz. Multiplicity of proton signals is indicated as follows: s (singlet), d (doublet), dd (double 
doublet), t (triplet), q (quartet), m (multiplet), br (broad), and approx (approximate). For 
spectroscopic assignments, glucopyranosyl carbon atoms are designated with 1\ 21, 31 ... , 
rhamnopyranosyl carbon atoms are designated with 1n, 2n, 3n ... , and diosgenyl carbon 
atoms are designated with 1 ', 2', 3' ... , etc. Optical rotations were measured with a Perkin 
Elmer 241 Polarimeter at room temperature (20-22 oC) and a Perkin Elmer 343 
Polarimeter at 22 °C. Low resolution electrospray ionization (ESI) mass spectra were 
obtained from a Biflex-IV MALDI linear/reflector instrument at the University of Manitoba, 
Canada, and high resolution (HR) ESI mass spectra were measured on the Applied 
Biosystems Mariner Biospectrometry Workstation at the University of Alberta, Canada. 
Elemental analyses were carried out on a CEC (SCP) 240-XAAnalyzer instrument by 
Lakehead University Instrumentation Laboratory (LUlL). 
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4.2 Synthetic procedures and structure characteristics 
3, 4, 6-Tri-O-acetyl -2-deoxy-2-(2, 2, 2-trich/oroethoxycarbony/amino )-0-( a-D-
glucopyranosy/) trichloroacetimidate (1 ): 
According to literature procedures,84 to a solution of 3,4,6-tri-0-acetyl -2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamino)-a/~-D-glucopyranose (5.52 g, 11.48 mmol) in anhydrous 
CH2Cb (20 ml), trichloroacetonitrile (CCbCN, 2.3 ml, 22.97 mmol) and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU, 0.17 ml, 1.15 mmol) were added drop-wise. The 
solution was stirred for 1 h at room temperature, the solvent was removed in vacuo, and 
the residue was purified with flash column chromatography (hexane/EtOAc/EhN, 2:1:0.01) 
to afford compound 1 (6.03 g, 84%) as a white solid. 





A suspension of 1 (5.48 g, 8. 77 mmol), diosgenin 2 (3.63 g, 8.64 mmol), and activated 
molecular sieves (4 A, 2.0 g) in anhydrous CH2Cb (50 ml) was stirred at room 
temperature for 15 min then cooled to ooc under N2 atmosphere. A solution of 
trimethylsilyl trifluoromethanesulfonate (TMSOTf, 8.0 ml, 0.02 Min dry CH2Cb) was 
added drop-wise. The mixture was stirred for 30 min, quenched by EhN (0.1 ml), and 
then filtered through Celite. The filtrate was concentrated in vacuo with the resulting 
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residue purified by flash column chromatography (CH2Cb/MeOH, 100:1) to give 
compound 3 (7.53 g, 98%) as a white foam. Rr 0.36 (hexane/acetone, 1.5:1 ); [a]~ -34.72 
(c 0.71, CHCb); 1H NMR (500 MHz, CDCb): 8 0.78 (s, 3H, CH3), 0.80 (d, 3H, J = 6.0 Hz, 
CH3), 0.98 (d, 3H, J = 7.0 Hz, CH3), 0.99 (s, 3H, CH3), 2.03 (s, 3H, CH3CO), 2.04 (s, 3H, 
CH3CO), 2.08 (s, 3H, CH3CO), 3.37 (dd, 1 H, J = 11.0, 11.0 Hz, H-26'a), 3.46-3.55 (m, 3H, 
H-26'b, H-3', H-2), 3.72 (m, 1 H, H-5), 4.09-4.15 (m, 1 H, H-6a), 4.28 (dd, 1 H, J = 12.0, 4.5 
Hz, H-6b), 4.41 (approx. q, 1H, J= 7.5 Hz, H-16'), 4.68 (d, 1H, J= 11.5 Hz, Troc-Ha), 4.79 
(d, 1 H, J = 11.5 Hz, Troc-Hb), 4.82 (d, 1 H, J = 8.5, H-1 ), 5.05 (dd, 1 H, J = 9.5, 10.0 Hz, H-
4 ), 5.31 (m, 1 H, H-6'), 5.38 (dd, 1 H, J = 9.5, 10.5 Hz, H-3), 5.48 (d, 1 H, J = 9.0 Hz, NH); 
13C NMR (125 MHz, CDCb): 814.35, 14.68, 16.42, 17.29, 19.51, 20.81, 20.87, 20.95, 
28.91, 29.54, 30.41, 31.49, 31.96, 32.18, 36.96, 37.24, 38.86, 39.86, 40.38, 41.72, 50.14, 
56.60, 60.60, 62.18, 62.38, 66.96, 69.05, 71.70, 71.92, 74.50, 79.96, 80.93, 95.65, 99.35, 
109.45, 122.02, 140.39, 154.17, 163.84, 169.71, 170.84, 170.94; ESI-HRMS m/z: 
[M + Naf Calcd for C42HsoN012CbNa: 898.3073, found: 898.3072. 
Diosgenyl 3,4, 6-tri-0-acetyl-2-amino-2-deoxy-~-o-g/ucopyranoside ( 4 ): 
To a solution of 3 (1.65 g, 1.88 mmol) in acetic acid (40 ml), zinc dust (4.0 g) was added 
and the mixture was stirred at room temperature for 16 h. The mixture was filtered and the 
solid was thoroughly washed with CH2Cb (100 ml). The filtrate was concentrated in vacuo 
and the residue was re-dissolved with CH2Cb (400 ml). The solution was washed with 
saturated NaHC03 solution (50 mL), dried with Na2S04, and concentrated under vacuum 
to give a white solid 4 (1.27 g, 96%) which was used without further purification in the next 
step. 
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Diosgenyl 3, 4, 6-tri-0-acetyl-2-acetamido-2-deoxy-~-o-g/ucopyranoside ( 5): 
To a cooled solution (ice water bath) of 4 (97 mg, 0.14 mmol) in pyridine (3.2 ml), acetic 
anhydride (2.5 ml) was added. The mixture was stirred at room temperature for 4 h. The 
solution was diluted with CH2Cb (150 ml) and washed successively with cold HCI solution 
(4 N, 100 ml), and saturated NaHC03 solution (50 ml x 2). The organic layer was dried 
over anhydrous NaS04 and concentrated under vacuum. The residue was subjected to 
flash column chromatography (hexane/CH2Cb/ethyl acetate, 3:3:7) to give the pure 
compound 5 (94 mg, 92%) as a white solid. Rt0.40 (CH2CI2/MeOH, 16:1); [a]~ -61.0 (c 
0.36 CHCb); 1H NMR (500 MHz, CDCb): 8 0.79 (s, 3H, CH3), 0.79 (d, 3H, J = 6.5 Hz, 
CH3), 0.87 (d, 3H, J = 7.0 Hz, CH3), 0.89 (s, 3H, CH3), 1.96 (s, 3H, CH3CO), 2.02 (s, 3H, 
CH3CO), 2.04 (s, 3H, CH3CO), 2.08 (s, 3H, CH3CO), 3.38 (dd, 1 H, J = 11.0, 11.0 Hz, H-
26'a), 3.48 (dd, 1H, J= 11.0, 4.5 Hz, H-26'b), 3.50 (m, 1H), 3.69-3.78 (m, 2H), 4.10 (dd, 
1 H, J = 12.0, 2.0 Hz, H-6a), 4.26 ( dd, 1 H, J = 12.0, 5.0 Hz, H-6b ), 4.40 (approx. q, 1 H, J ~ 
8.0 Hz, H-16'), 4.85 (d, 1 H, J = 8.0 Hz, H-1 ), 5.05 (dd, 1 H, J = 9.5, 9.5 Hz, H-4), 5.34 (m, 
1 H, H-6'), 5.38 (dd, 1 H, J = 9.5, 9.5 Hz, H-3), 5.46 (d, 1 H, J = 8.5 Hz, NH); 13C NMR (125 
MHz, CDCb): 814.34, 14.74, 16.49, 17.35, 19.59, 21.02, 22.87, 23.64, 29.00, 29.64, 
29.92, 30.50, 31.59, 31.80, 32.04, 32.23, 37.06, 37.35, 39.04, 39.94, 40.47, 41.811 50.23, 
55.71 I 56.68, 62.27, 62.48, 67.07, 69.02, 71.84, 72.35, 79.811 81.02, 99.45, 109.53, 
122.10, 140.57, 169.10, 170.50, 170.80, 171.10; ESI-HRMS m/z: [M + Nar Calcd for 
C41H51N011Na: 766.4137, found: 766.4140. 
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Diosgenyl 3,4, 6-tri-0-acety/-2-benzamido-2-deoxy-~-o-g/ucopyranoside (6): 
~~c 
A).c~O ob 
To a cooled solution (ice water bath) of 4 (160 mg, 0.23 mmol) in pyridine (2.0 ml), 
benzoyl chloride (0.03 ml, 0.26 mmol) was added. The mixture was stirred at room 
temperature for 4 h. The solution was diluted with EtOAc (150 ml), washed with cold HCI 
solution (4 N, 50 ml) and saturated NaHC03 solution (50 ml x 3). The organic layer was 
dried over anhydrous NaS04 and concentrated under vacuum. The residue was subjected 
to flash column chromatography (hexane/CH2Cb/ethyl acetate) 3:3:1.5 to give the pure 
compound 6 (155 mg, 84%) as a white solid. Rt 0.56 (CH2Cb/MeOH, 25:1); [a]~ -34.7 (c 
0.36 CHCb); 1H NMR (500 MHz, CDCb) 8 0.76 (s, 3H, CH3), 0.78 (d, 3H, J = 5.5 Hz, CH3), 
0.95 (s, 3H, CH3), 0.96 (d, 3H, J = 7.5 Hz, CH3), 1.99 (s, 3H, CH3CO), 2.03 (s, 3H, 
CH3CO), 2.09 (s, 3H, CH3CO), 3.37 (dd, 1 H, J = 11.0, 11.0 Hz, H-26'a), 3.46 (dd, 1 H, J = 
11.0, 3.5 Hz, H-26'b), 3.50 (m, 1H, H-2), 3.76-3.78 (m, 1H, H-5), 3.98 (m, 1H, H-3), 4.11 
(brd, 1 H, J = 11.5 Hz, H-6a), 4.30 (dd, 1 H, J = 12.0, 4.7 Hz, H-6b), 4.39 (approx. q, 1 H, J 
:::: 7.5 Hz, H-16'), 4.95 (d, 1 H, J = 8.0 Hz, H-1 ), 5.12 (dd, 1 H, J = 9.5, 9.5 Hz, H-4), 5.25 
(m, 1 H, H-6'), 5.52 (dd, 1 H, J = 9.5, 9.5 Hz, H-3), 6.23 (d, 1 H, J = 9.0 Hz, NH), 7.40-7.51 
(m, 3H, 3 Ar-H), 7.70 (m, 2H, 2 Ar-H); 13C NMR (125 MHz, CDCb): 8 14.71, 16.45, 17.33, 
19.53, 20.91' 21.01' 28.97, 29.62, 30.47, 31.55, 32.00, 32.22, 37.00, 37.34, 38.99, 39.91' 
40.43, 41.77, 50.19, 55.84, 56.64, 62.24, 62.53, 67.03, 68.69, 71.94, 72.43, 79.95, 80.98, 
99.75, 109.49, 121.96, 127.02, 128.90, 131.90, 134.54, 140.56, 167.91, 169.69, 170.98, 
171.16; ESI-HRMS m/z: [M + Nat Calcd for C4sHs3N011 Na: 828.4293, found: 828.4289. 
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To a cooled solution (ice water bath) of 4 (193 mg, 0.27 mmol) in pyridine (3.0 ml), 
succinic anhydride (33 mg, 0.33 mmol) was added. The mixture was stirred at room 
temperature for 4 h. The solvent was removed in vacuo and the residue was diluted with 
CH2Cb (150 ml) and washed with ice water (20 ml x 2). The organic layer was dried over 
anhydrous NaS04 and concentrated under vacuum. The residue was subjected to flash 
column chromatography (CH2Cb/MeOH) 25:1 to give the pure compound 7 (141 mg, 
73%) as a white solid. Rt 0.43 (CH2Cb/Me0H, 12:1); [a]2~ -58.8 (c 0.11 CHCb); 1H NMR 
(500 MHz, CDCb): 8 0.78 (s, 3H, CH3), 0.79 (d, 3H, J = 7.0 Hz, CH3), 0.95 (d, 3H, J = 7.5 
Hz, CH3), 1.00 (s, 3H, CH3), 2.01 (s, 3H, CH3CO), 2.02 (s, 3H, CH3CO), 2.07 (s, 3H, 
CH3CO), 2.46 (t, 2H, J = 7.5 Hz, CH2CO), 2.70 (m, 2H, CH2CO), 3.37 (dd, 1 H, J = 11.0, 
11.0 Hz, H-26'a), 3.45 (dd, 1H, J = 11.0, 5.0 Hz, H-26'b), 3.70-3.77 (m, 2H, H-5, H-3'), 
4.10 (dd, 1 H, J = 12.5, 2.5 Hz H-6a), 4.26 (dd, 1 H, J = 12.5, 5.5 Hz, H-6b), 4.39 (approx. 
q, 1H, J~ 8.0 Hz, H-16'), 4.85 (d, 1H, J = 8.0 Hz, H-1), 5.02 (dd, 1H, J = 10.0, 10.0 Hz, 
H-4), 5.32 (m, 1 H, H-6'), 5.37 (dd, 1 H, J = 1 0.0, 10.0 Hz, H-3), 6.03 (d, 1 H, J = 8.5 Hz, 
NH); ESI-HRMS m/z: [M + Naf Calcd for C43H53N013Na: 824.4192, found: 824.4193. 
Oiosgenyl 3, 4, 6-tri-0-acetyi-2-[(S)-2-acetamido-propanamidoj-2-deoxy-p-o-
glucopyranoside (Sa): 
46 
To a solution of 4 (300 mg, 0.43 mmol) in dry DMF (5.0 ml), N-acetyi-L-alanine (56 mg, 
0.43 mmol), diisopropylethylamine (DIPEA, 0.15 ml, 0.86 mmol), and 2-(1 H-
benzotriazole-1-yl)-1, 1 ,3,3-tetramethylaminium hexafluorophosphate (HBTU, 163 mg, 
0.43 mmol) were added and the mixture was stirred for 16 h. The solvent was removed in 
vacuo and the residue was dissolved with CH2Cb (150 ml) and washed with H20 (10 ml 
x 2). The organic layer was dried over anhydrous NaS04 and concentrated under 
vacuum. The residue was subjected to flash column chromatography (CH2Cb/Me0H, 
25:1) to give compound Sa (272 mg, 78%) as a white solid. Rt 0.36 (CH2Cb/MeOH, 25:1 ); 
[af~ -53.2 (c 0.64, CHCb); 1H NMR (500 MHz, CDCb): 8 0.81 (s, 3H, CH3), 0.82 (d, 3H, J 
= 6.0 Hz, CH3), 0.98 (d, 3H, J = 7.0 Hz, CH3), 1.02 (s, 3H, CH3), 1.99 (s, 3H, CH3CO), 
2.01 (s, 3H, CH3CO), 2.04 (s, 3H, CH3CO), 2.10 (s, 3H, CH3CO), 3.37 (m, 1 H, H-26'a), 
3.48-3.51 (m, 2H, H-26'b, H-2), 3.74-3.83 (m, 2H, H-3', H-5), 4.12 (dd, 1 H, J = 12.0, 2.0 
Hz, H-6a), 4.29 (m, 1H, J = 12.0, 4.5 Hz, H-6b), 4.29 (m, 1H, CHNHAc), 4.43 (approx. q, 
1 H, J =:J 7.5 Hz, H-16'), 4.80 (d, 1 H, J = 8.5 Hz, H-1 ), 4.91 (dd, 1 H, J = 9.5, 9.5 Hz, H-4), 
5.20 (dd, 1 H, J = 1 0.5, 10.5 Hz, H-3), 5.26 (m, 1 H, H-6'), 7.62 (d, 1 H, J = 7.5 Hz, NH), 
7.87 (d, 1H, J = 8.5 Hz, NH); 13C NMR (125 MHz, CDCb): 814.74, 16.50, 17.35, 18.27, 
19.59, 20.90, 21.01' 23.40, 29.01, 29.67, 30.51' 31.60, 32.05, 32.27, 37.04, 37.34, 39.03, 
39.95, 40.47, 41.82, 49.15, 50.26, 55.32, 56.69, 62.30, 62.52, 67.07, 69.10, 71.81, 72.31, 
79.88, 81.00, 98.15, 108.16, 120.68, 139.30, 168.34, 169.00, 169.60, 169.61, 171.54; 
ESI-HRMS m/z: [M + Naf Calcd for C44H55N2012Na: 837.4508, found: 837.4506. 






To a solution of 4 (150 mg, 0.21 mmol) in dry DMF (5.0 mL), (±)-a-lipoic acid (44 mg, 0.21 
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mmol), DIPEA (0.075 ml, 0.43 mmol), and HBTU (82 mg, 0.21 mmol) were added and 
the mixture was stirred for 16 h. The solvent was removed in vacuo and the residue was 
dissolved with CH2Cb (150 ml) and washed with H20 (1 0 ml x 2). The organic layer was 
dried over anhydrous NaS04 and concentrated under vacuum. The residue was subjected 
to flash column chromatography (hexane/EtOAc/MeOH, 1:1 :0.025) to give compound 9 
(158 mg, 83%) as a white solid. Rt0.32 (hexane/EtOAc/MeOH, 1:1:0.025); [a]~ -175.0 (c 
0.03 CHCb); 1H NMR (500 MHz, CDCb): 8 0.78 (s, 3H, CH3), 0.79 (d, 3H, J = 6.5 Hz, 
CH3), 0.96 (d, 3H, J = 7.0 Hz, CH3), 0.99 (s, 3H, CH3), 2.01 (s, 3H, CH3CO), 2.02 (s, 3H, 
CH3CO), 2.07 (s, 3H, CH3CO), 2.23 (m, 1 H, CHHCO), 2.45 (m, 1 H, CHHCO), 3.08-3.20 
(m, 2H, CH2S), 3.17 (m, 1 H), 3.37 (dd, 1 H, J = 1 0.5, 10.5 Hz, H-26'a), 3.45-3.56 (m, 3H, 
H-26'b, H-2, CHS), 3.65 (m, 1 H, H-3') 3.70 (m, 1 H, H-5), 4.09 (dd, 1 H, J = 12.0, 2.5 Hz, H-
6a), 4.26 (dd, 1 H, J = 12.0, 5.0 Hz, H-6b), 4.40 (approx. q, 1 H, J r:.:: 7.5 Hz, H-16'), 4.89 
(two sets of dd, each 0.5H, J = 8.0 Hz, H-1), 5.03 (dd, 1H, J = 9.5, 9.5 Hz, H-4), 5.33 (m, 
1H, H-6'), 5.41 (two sets of dd, each 0.5H, J = 10.0, 10.0 Hz, H-3), 5.48 (two sets of d, 
each 0.5H, J = 8.5 Hz, NH); 13C NMR (125 MHz, CDCb): 8 14.72, 16.49, 17.34, 19.59, 
20.88, 20.96, 25.42, 25.47, 28.98, 29.64, 30.48, 31.59, 32.04, 32.28, 34.78, 34.83, 36.67, 
37.04, 37.32, 38.65, 39.11' 39.92, 40.45, 41.79, 50.21' 55.73, 56.07, 56.58, 56.66, 62.26, 
62.49, 67.04, 69.08, 71.81, 72.27, 79.72, 79.95, 80.99, 99.32, 109.50, 122.11, 140.54, 
169.71, 170.98, 170.99, 172.98; ESI-HRMS m/z: [M + Nar Calcd for C47H71N011S2Na: 
912.4360, found: 912.4358. 





Compound 5 (100 mg, 0.13 mmol) was dissolved in MeOH/CH2Cb (2:1, 9 ml) and then 
NaOMe solution in methanol (0.6 ml) was added until pH 10. After stirring for 4 h at room 
temperature, the mixture was neutralized by adding weak acidic ion-exchange resin 
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(Amberlite IRC-50, H+ form). The resin was filtered and the filtrate concentrated in vacuo. 
The residue was applied to a Sephadex LH-20 gel filtration column (MeOH/CH2Cb, 2:1) to 
yield compound 10 (81 mg, 98%) as a white solid. Rt 0.21 (CH2Cb/MeOH, 12:1); [a]~ -
66.6 (c0.26, CH30H/CHCb, 1:1); lit. 81 [a]~ -75 (c0.5, CH30H/CHCb, 1:1); 1H NMR (500 
MHz, C505N plus two drops of CD30D): 8 0.73 (d, 3H, J = 6.0 Hz, CH3), 0.84 (s, 3H, CH3), 
0.96 (s, 3H, CH3), 1.18 (d, 3H, J = 7.0 Hz, CH3), 2.18 (s, 3H, CH3CO), 3.50 (dd, 1 H, J = 
10.5, 10.5 Hz, H-26'a), 3.60 (dd, 1H, J =10.5, 3.5 Hz, H-26'b), 3.83-3.88 (m, 1H, H-3'), 
3.91-3.94 (m, 1 H, H-5), 4.14 (m, 1 H, H-2), 4.30 (dd, 1 H, J = 12.0, 6.0 Hz, H-6a), 4.37-
4.44 (m, 2H, H-3, H-4), 4.50 (dd, 1 H, J = 10.0, 2.0 Hz, H-6b), 4.55 (approx. q, 1 H, J = 7.0 
Hz, H-16'), 5.21 (d, 1 H, J = 7.5 Hz, H-1 ), 5.35 (m, 1 H, H-6'), 8.89 (d, 1 H, J = 8.0 Hz, NH); 
13C NMR (125 MHz, C5D5N plus two drops of CD30D): 8 15.54, 16.86, 17.82, 19.92, 
21.57, 24.08, 29.73, 30.64, 31.07, 32.12, 32.28, 32.66, 32.74, 37.50, 37.91, 40.00, 40.34, 
40.93, 42.43, 50.71, 57.13, 58.49, 63.13, 63.34, 67.33, 72.81, 76.76, 78.98, 78.99, 81.57, 
101.27, 109.74, 122.20, 141.44, 171.01; ESI-MS m/z: [M + Ht Calcd for C35H56N08: 
618.83, found: 618.64. The NMR spectral data are in general agreement with the reported 
data81 which were measured in DMSO-d5. 




In a similar way as described for the preparation of 10, compound 6 (71 mg, 0.09 mmol) 
was treated with sodium methoxide in MeOH/CH2Cb (2:1) to give 11 (57 mg, 95%) as a 
white solid. Rt0.18 (CH2Cb/MeOH, 12:1); [a]2~ -28.0 (c0.16, CHCb/MeOH, 1:1); 1H NMR 
(500 MHz, C50 5N): 8 0.69 (d, 3H, J = 5.5 Hz, CH3), 0.82 (s, 3H, CH3), 0.83 (s, 3H, CH3), 
1.14 (d, 3H, J = 6.0 Hz, CH3), 2.43 (m, 1 H), 2.69 (m, 1 H), 3.50 (dd, 1 H, J = 1 0.5, 10.5 Hz, 
H-26'a), 3.59 (dd, 1 H, J = 1 0.5, 3.0 Hz, H-26'b), 3.90 (m, 1 H, H-3'), 4.06 (m, 1 H, H-5), 
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4.32 (m, 1 H, H-6a), 4.43 (m, 1 H, H-2), 4.54 (approx. q, 1 H, J = 7.5, 7.5 Hz, H-16'), 4.60 
(brd, 1 H, J = 11.0 Hz, H-6b), 4.68-4.80 (m, 2H, H-3, H-4), 5.22 (m, 1 H, H-6'), 5.56 (d, 1 H, 
J = 8.5 Hz, H-1 ), 6.58 (s, 1 H, 0-H), 7.37-7.44 (m, 5H, 3 Ar-H, 2 OH), 8.39 (d, 2H, J = 6.5 
Hz, 2 Ar-H), 9.44 (d, 1 H, J = 8.0 Hz, NH); 13C NMR (125 MHz, C505N): 8 15.51, 16.80, 
17.80, 19.80, 21.511 29.711 30.47, 30.64, 31.05, 32.04, 32.25, 32.68, 37.43, 37.87, 40.09, 
40.28, 40.89, 42.40, 50.64, 57.07, 59.47, 63.31, 67.31 I 73.1 0, 76.30, 79.1 0, 79.17, 81.54, 
101.16, 109.71, 122.19, 128.51, 129.06, 131.67, 137.32, 141.26, 141.28, 168.94; ESI-MS 
m/z: [M + Ht Calcd for C4oH5sNOs: 680.41, found: 680.69. 






In a similar way as described for the preparation of 10, Compound 7 (66 mg, 0.08 mmol) 
was treated with sodium methoxide in MeOH/CH2Cb (2: 1) to give 12 (55 mg, 
quantitatively) as a white solid. Rt 0.28 (CHCb/MeOH/H20, 6:4:0.5); [a]~ -29.4 (c 0.14 
CHCb/MeOH, 1:1 ); 1H NMR (500 MHz, CD30D): 8 0.69 (s, 3H, CH3), 0.70 (d, 3H, J = 5.5 
Hz, CH3), 0.86 (d, 3H, J = 7.0 Hz, CH3), 0.93 (s, 3H, CH3), 2.40 (m, 4H), 3.14-3.26 (m, 
3H), 3.32-3.50 (m, 3H), 3.54-3.60 (m, 1H), 3.74-3.82 (m, 1H), 4.29 (approx. q, 1H, J = 7.5 
Hz, H-16'), 4.46 (d, 1H, J = 8.0 Hz, H-1), 4.63-4.68 (m, 1H), 5.27 (m, 1H, H-6'), 8.89 (d, 
1H, J= 9.5 Hz, NH); 13C NMR (125 MHz, CD30D): 815.90, 16.96, 17.69, 20.04, 22.16, 
30.07, 30.83, 31.63, 32.61, 32.96, 32.97, 33.10, 33.36, 33.58, 38.15, 38.68, 40.18, 41.10, 
41.60, 43.08, 51.84, 57.97, 57.98, 63.00, 63.92, 68.03, 72.15, 76.20, 78.05, 80.42, 82.38, 
101.28, 110.74, 122.80, 142.09, 175.93, 178.86; ESI-MS m/z: [M +Nat Calcd for 
C37H57N01oNa: 698.85, found: 698.86. 
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Diosgenyl 2-[(S)-2-acetamido-propanamido]-2-deoxy-p-o-g/ucopyranoside (13): 
In a similar way as described for the preparation of 10, compound Sa (168 mg, 0.21 
mmol) was treated with sodium methoxide in MeOH/CH2Cb (2:1) to give 13 (141 mg, 
quantitatively) as a white solid. Rr 0.21 (CH2Cb/MeOH, 8:1 ); [a]2~ -44.8 (c 0.36, 
CHCb/MeOH, 1:1 ); 1H NMR (500 MHz, CDCb/CD30D, 1:1 ): 8 0.71 (s, 3H, CH3), 0.72 (d, 
3H, J = 5.0 Hz, CH3), 0.88 (d, 3H, J = 7.0 Hz, CH3), 0.92 (s, 3H, CH3), 1.29 (d, 3H, J = 7.0 
Hz, CH3), 1.91 (s, 3H, CH3CO), 3.21 (m, 1 H), 3.26 (m, 1 H), 3.30 (m, 1 H), 3.38 (m, 1 H), 
3.40-3.51 (m, 1 H), 3.64 (dd, 1 H, J = 12.0, 5.0 Hz, H-6a), 3. 78 (dd, 1 H, J = 12.0, 2.5 Hz, 
H-6b), 4.24 (q, 1 H, J = 7.0 Hz, CHNHAc), 4.33 (approx. q, 1 H, J = 7.5 Hz, H-16'), 4.47 (d, 
1 H, J = 8.0 Hz, H-1 ), 5.25 (m, 1 H, H-6'); 13C NMR (125 MHz, CDCb/CD30D, 1:1 ): 8 15.63, 
17.56, 18.27, 18.95, 20.59, 22.29, 23.66, 30.10, 30.89, 31.65, 32.71, 32.92, 33.10, 33.50, 
38.27, 38.65, 40.21, 41.17, 41.75, 43.11, 50.73, 51.63, 57.98, 58.58, 63.22, 63.53, 68.33, 
72.33, 75.40, 77.57, 80.53, 82.53, 100.65, 111.14, 123.11, 141.95, 173.20, 175.20; ESI-
MS m/z: [M +Nat Calcd for C3aH6oNz0gNa: 711.42, found: 711.57. 





In a similar way as described for the preparation of 10, compound 9 (139 mg, 0.16 mmol) 
was treated with sodium methoxide in MeOH/CHzCiz (2: 1) to give 14 ( 119 mg, 
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quantitatively) as a white solid. Rt 0.24 (CH2Cb/MeOH, 12:1 ); [a]2~ -44.8 (c 0.21 
CHCb/MeOH, 1:1 ); 1H NMR (500 MHz, C50 5N): 8 0.70 (d, 3H, J = 5.5 Hz, CH3), 0.85 (s, 
3H, CH3), 0.99 (s, 3H, CH3), 1.15 (d, 3H, J =·7.0 Hz, CH3), 2.22 (m, 1 H), 2.48 (t, 2H, J = 
7.0 Hz), 2.54 (m, 1H), 2.72 (m, 1H), 2.97-3.08 (m, 2H, CH3S), 3.47-3.53 (m, 2H, H-26'a, 
CHS), 3.60 (dd, 1H, J = 12.0, 3.5 Hz, H-26'b), 3.87-3.94 (m, 1H, H-3'), 4.00 (m, 1H, H-5), 
4.25 (dd, 1 H, J = 9.0, 9.0 Hz, H-4), 4.40 (dd, 1 H, J = 12.0, 5.5 Hz, H-6a), 4.50-4.59 (m, 
4H, H-2, H-3, H-6b, H-16'), 5.32 (two sets of d, each O.SH, J = 8.0 Hz, H-1 ), 5.36 (m, 1 H, 
H-6'), 8.82 (d, 1H, J= 7.5 Hz, NH); 13C NMR (125 MHz, C50 5N): 815.51, 16.83, 17.79, 
19.99, 21.57, 26.54, 29. 74, 30.68, 31.06, 32.14, 32.26, 32.66, 32. 76, 35.46, 37.28, 37.52, 
37.89, 39.12, 40.14, 40.32, 40.86, 40.92, 42.42, 50.70, 57.12, 57.28, 58.45, 63.20, 63.33, 
67.31, 72.99, 76.79, 78.89, 79.02, 81.54, 101.22, 109.72, 122.25, 141.45, 173.74; ESI-MS 
m/z: [M + Hr Calcd for C41H55NOaS2: 764.42, found: 764.70. 
Diosgenyl 3, 4, 6-tri-0-acety/-2-(5-carboxy/pentamido)-2-deoxy-p-o-g/ucopyranoside (15) 








In a similar way as described for the preparation of Sa, compound 4 (130 mg, 0.19 mmol) 
was treated with adipic acid (12 mg, 0.085 mmol), DIPEA (0.064 ml, 0.37 mmol), and 
HBTU (70 mg, 0.19 mmol) in dry DMF (5.0 ml) to the monomeric product 15 (15 mg, 
21%) and the dimeric product 16 (71 mg, 56%). For 15: Rt0.24 (hexane/EtOAc/MeOH, 
1:1:0.1 ); [af~ -36.8 (c 0.25, CHCb); 1H NMR (500 MHz, CDCb): 8 0.78 (s, 3H, CH3), 0.79 
(d, 3H, J = 7.0 Hz, CH3), 0.96 (d, 3H, J = 7.0 Hz, CH3), 0.99 (s, 3H, CH3), 2.01 (s, 6H, 2-
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CH3CO), 2.07 (s, 3H, CH3CO), 2.07 (s, 3H, CH3CO), 2.29 (m, 2H), 2.34 (m, 2H), 3.37 (dd, 
1 H, J = 11.0, 11.0 Hz, H-26'a), 3.46-3.52 (m, 2H, H-26'b, H-2), 3.72-3.77 (m, 2H, H-5, H-
3'), 4.10 (dd, 1 H, J = 12.0, 1.5 Hz, H-6a), 4.28 (dd, 1 H, J = 12.0, 4.5 Hz, H-6b), 4.41 
(approx. q, 1 H, J ~ 7.5 Hz, H-16'), 4.85 (d, 1 H, J = 8.5 Hz, H-1 ), 5.03 (dd, 1 H, J = 9.5, 
10.0 Hz, H-4), 5.31 (m, 1 H, H-6'), 5.38 (dd, 1 H, J = 9.5, 10.5 Hz, H-3), 5.86 (d, 1 H, J = 9.0 
Hz, NH); 13C NMR (125 MHz, CDCb): 814.73, 16.50, 17.35, 19.58, 20.88, 20.96, 21.02, 
21.03, 24.30, 24.99, 28.98, 29.63, 29.91, 30.47, 31.56, 31.57, 32.03, 32.26, 36.36, 37.03, 
37.33, 39.05, 39.93, 40.45, 41.79, 50.21, 55.37, 56.67, 62.24, 62.53, 67.05, 69.14, 71.75, 
72.50, 79.76, 81.00, 99.44, 109.54, 122.03, 140.57, 169.73, 171.00, 171.22, 173.12, 
178.16; ESI-MS m/z: [M + Ht Calcd for C4sH5aN013: 830.47, found: 830.71. 
For 16: Rt 0.29 (hexane/EtOAc/MeOH, 1:1:0.1); [a]~ -61.7 (c 0.29, CHCb); 1H NMR (500 
MHz, CDCb): 8 0.78 (s, 3H, CH3), 0.80 (d, 3H, J = 7.0 Hz, CH3), 0.97 (d, 3H, J = 7.0 Hz, 
CH3), 0.99 (s, 3H, CH3), 2.02 (s, 3H, CH3CO), 2.03 (s, 3H, CH3CO), 2.08 (s, 3H, CH3CO), 
2.19 (m, 2H), 3.37 (dd, 1 H, J = 11.0, 11.0 Hz, H-26'a), 3.48 (dd, 1 H, J = 11.0, 4.0 Hz, H-
26'b), 3.50 (m, 1H, H-2), 3.73-3.81 (m, 2H, H-5, H-3'), 4.10 (dd, 1H, J = 12.0, 2.5 Hz, H-
6a), 4.28 (dd, 1 H, J = 12.0, 5.0 Hz, H-6b), 4.41 (approx. q, 1 H, J ~ 7.5 Hz, H-16'), 4.90 (d, 
1 H, J = 8.5 Hz, H-1 ), 5.06 (dd, 1 H, J = 9.5, 10.0 Hz, H-4), 5.29 (m, 1 H, H-6'), 5.45 (dd, 1 H, 
J= 9.5, 10.5 Hz, H-3), 6.13 (d, 1H, J= 8.5 Hz, NH); 13C NMR (125 MHz, CDCb): 814.74, 
16.51 1 17.36, 19.61 I 20.91 I 21.03, 21.1 0, 24.31 I 28.99, 29.611 29.91 I 30.50, 31.58, 31.59, 
32.04, 32.28, 36.06, 37.06, 37.35, 39.05, 39.92, 40.46, 41.80, 50.23, 55.34, 56.67, 62.26, 
62.49, 67.06, 69.25, 71.72, 72.76, 79.59, 80.98, 99.33, 109.52, 121.97, 140.69, 169.70, 
170.98, 171.17, 173.01; ESI-HRMS m/z: [M + Nar Calcd for Ca4H124NzOzzNa: 1535.8538, 
found: 1535.8533. 







In a similar way as described for the preparation of 10, compound 15 (26 mg, 0.03 mmol) 
was converted to 17 (22 mg, quantitatively) as a white solid. Rt 0.20 (CH2Ciz/MeOH, 12:1 ); 
[af~ -14.0 (c 0.14, CHCb/MeOH, 1:1 ); 1H NMR (500 MHz, C5D5N): 8 0.68 (d, 3H, J = 5.0 
Hz, CH3), 0.81 (s, 3H, CH3), 0.95 (s, 3H, CH3), 1.13 (d, 3H, J = 7.0 Hz, CH3), 2.52 (m, 5H), 
2. 70 (m, 1 H), 3.50 (dd, 1 H, J = 1 0.5, 10.5 Hz, H-26'a), 3.58 (dd, 1 H, J = 1 0.5, 3.5 Hz, H-
26'b), 3.88 (m, 1H, H-3'), 3.97 (m, 1H, H-5), 4.21 (dd, 1H, J = 9.0, 9.0 Hz, H-4), 4.36 (dd, 
1 H, J = 12.0, 5.5 Hz, H-6a), 4.43-4.58 (m, 4H, H-2, H-3, H-6b, H-16'), 5.25 (d, 1 H, J = 7.5 
Hz, H-1 ), 5.33 (m, 1 H, H-6'), 8.82 (d, 1 H, J = 8.0 Hz, NH); 13C NMR (125 MHz, C5D5N): 
8 15.30, 16.62, 17.59, 19.73, 21.34, 25.60, 26.39, 29.51, 30.49, 30.85, 31.87, 32.05, 
32.43, 32.50, 34.92, 37.18, 37.28, 37.69, 39.80, 40.11, 40.70, 42.31, 50.49, 56.89, 58.28, 
63.11, 64.74, 67.11, 72.83, 76.70, 78.74, 78.83, 81.34, 101.04, 109.52, 121.94, 141.29, 
173.64, 176.06; ESI-MS m/z: [M + Ht Calcd for C39Hs2N010: 704.92, found: 704.71. 
N, N'-Bis( diosgenyl 2-deoxy-p-o-glucopyranosid-2-y/) hexandiamide ( 18): 
In a similar way as described for the preparation of 10, compound 16 (27 mg, 0.02 mmol) 
was convertedto 18 (22 mg, 98%) as a white solid. Rt 0.35 (CH2Ciz/MeOH, 5:1 ); [a]~ -
39.2 (c 0.14, CHCb/MeOH, 1 :1); 1H NMR (500 MHz, C5D5N): 8 0.68 (d, 3H, J = 5.5 Hz, 
CH3), 0.86 (s, 3H, CH3), 0.95 (s, 3H, CH3), 1.15 (d, 3H, J = 7.0 Hz, CH3), 2.49 (m, 1 H), 
2.55 (m, 1 H), 2.68 (m, 1 H), 3.50 (dd, 1 H, J = 1 0.5, 10.5 Hz, H-26'a), 3.59 (dd, 1 H, J = 
1 0.5, 2.5 Hz, H-26'b), 3.89 (m, 1 H, H-3'), 3.95 (m, 1 H, H-5), 4.21 (dd, 1 H, J = 9.0, 9.0 Hz, 
H-4), 4.36 (dd, 1H, J= 12.0, 5.5 Hz, H-6a), 4.45 (dd, 1H, J= 10.0, 9.0 Hz, H-3),4.52-4.58 
(m, 3H, H-2, H-6b, H-16'), 5.25 (d, 1H, J = 8.5 Hz, H-1), 5.32 (m, 1H, H-6'), 8.75 (d, 1H, J 
= 9.0 Hz, NH); 13C NMR (125 MHz, C5D5N): 815.52, 16.89, 17.80, 19.96, 21.58, 26.20, 
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29.731 30.691 31.061 32.121 32.281 32.691 32.76, 37.20, 37.51 I 37.89, 39.92, 40.331 40.94, 
42.44, 50.711 57.121 58.36, 63.281 63.341 67.321 72.931 76.951 78.801 79.01 I 81.561 
101.161 109.73, 122.21 1 141.41 1 174.09; ESI-HRMS m/z: [M + Nar Calcd for 
C72H112N201sNa: 1283.7904, found: 1283.7903. 
3, 6-Di-0-benzoy/-2-deoxy-2-(2, 2, 2-trich/oroethoxycarbonylamino )-a!p-D-glucopyranose 
(20) and 3, 4, 6-Tri-0-benzoy/-2-deoxy-2-(2, 2, 2-trich/oroethoxycarbony/amino )-a!p-o-







To a solution of 19 (3.0 g, 8.46 mmol) and 4-dimethylaminopyridine (DMAPI 103 mg, 0.10 
mmol) in anhydrous pyridine (9 ml) and dry CH2Cb (6 ml)1 benzoyl chloride (2.06 ml, 
17.77 mmol) in dry CH2Cb (8 ml) was added drop-wise under N2 atmosphere at -40 °C. 
The reaction was carefully monitored by TLC every fifteen minutes. After being stirred at 
room temperature for 2 h, the mixture was quenched with MeOH. The solution was then 
diluted with CH2Cb (200 ml) and washed with cold HCI solution (4 N, 30 ml) and 
saturated NaHC03 solution (30 ml). The organic layer was dried over anhydrous NaS04 
and concentrated under vacuum. The residue was subjected to flash column 
chromatography (hexane/EtOAc, 1.5:1) to yield compound 20 (3.43 g, 72%) as a white 
foam and 21 (666 mg, 14%) both as anomeric mixtures (alp, 8:1). For 20a.: Rt 0.26 
(hexane/EtOAc, 1.5:1 ); [a]~ 0 (c 0.50 CHCb); 1H NMR (500 MHz, CDCb): 8 3.40 (brs, 1 H, 
OH), 3.69 (brs, 1 H, OH), 3.87 (dd, 1 H, J = 1 0.0, 9.5 Hz, H-4), 4.21 (m, 1 H, H-2)1 4.34 (m, 
1 H, H-5), 4.41 (d, 1 H, J = 12.0 Hz, Troc-Ha), 4.66 (dd, 1 H, J = 12.0, 2.0 Hz, H-6a), 4.74 
(dd, 1H, J= 12.0, 4.0 Hz, H-6b), 4.76 (d, 1H, J= 12.0 Hz, Troc-Hb), 5.40 (d, 1H, J= 3.5 
Hz, H-1 ), 5.65 (dd, 1 H, J = 1 0.5, 9.5 Hz, H-3), 5.81 (d, 1 H, J = 9.0 Hz, NH), 7.44 (m, 4H, 4 
Ar-H), 7.57 (m, 2H, 2 Ar-H), 8.04 (m, 4H, 4 Ar-H); 13C NMR (125 MHz, CHCb): 8 54.06, 
63.58, 69.63, 70.80, 74.44, 74.68, 92.44, 95.45, 128.68, 129.13, 129.80, 130.08, 130.31' 
133.57, 133.91, 154.43, 167.23, 168.07; Anal. Calcd for C23H22CbNOg: C, 49.09; H, 3.94; 
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N, 2.49. Found: C, 49.68; H, 3.84; N, 2.23. 
For 21 a: Rt 0.48 (hexane/EtOAc, 1.5:1 ); [a]~ +26.4 (c 0.50 CHCb); 1H NMR (500 MHz, 
CDCI3): 8 3.92 (brs, 1 H, OH), 4.33 (m, 1 H, H-2), 4.41 (dd, 1 H, J = 12.5, 4.0 Hz, H-6a), 
4.47 (d, 1H, J = 12.0 Hz, Troc-Ha), 4.63-4.69 (m, 2H, H-5, H-6b), 4.70 (d, 1H, J = 12.0 Hz, 
Troc-Hb), 5.47 (s, 1H, H-1), 5.70 (d, 1H, J= 10.0 Hz, NH), 5.72 (dd, 1H, J= 9.5, 10.0 Hz, 
H-4), 5.90 (dd, 1H, J= 10.5, 10.0 Hz, H-3), 7.26-7.57 (m, 10H, 10Ar-H), 7.92 (m, 3H, 3 
Ar-H), 8.05 (m, 2H, 2Ar-H); 13C NMR (125 MHz, CHCb): 8 54.73, 63.00, 68.40, 69.49, 
71.41, 74.54, 92.31, 95.37, 128.60, 128.63, 128.97, 129.03, 129.71, 130.01, 130.15, 
133.43, 133.64, 154.43, 165.42, 166.63, 166.87; Anal. Calcd for C3oHz6CbN010: C, 54.03; 
H, 3.93; N, 2.1 0. Found: C, 54.03; H, 3.92; N, 1.89. 
2, 3, 4-Tri-0-acety/-a-L-rhamnopyranosy/-( 1 --4 )-3, 6-di-0-benzoyl-2-deoxy-2-(2,2,2-





A suspension of 20 (5.0 g, 8.88 mmol), 23 (3.88 g, 8.88 mmol), and activated molecular 
sieves (4 A, 3.0 g) in anhydrous CH2Ciz (15 ml) was stirred under N2 atmosphere at room 
temperature for 30 min, then cooled to -20 °C. A solution of trimethylsilyl 
trifluoromethanesulfonate (TMSOTf, 5.5 ml, 0.02 M in dry CH2Ciz) was added drop-wise. 
The mixture was stirred for 30 min, quenched by saturated NaHC03 solution (1 0 ml), 
extracted with CH2CI2 (3 x 20 ml) and dried over NaS04.The filtrate was concentrated in 
vacuo with the resulting residue purified by flash column chromatography (hexane/EtOAc, 
1.5:1) to give compound 24 (5.26 g, 71%) as a white foam. R, 0.29 (hexane/EtOAc, 1.5:1 ); 
[a]~ +19.8 (c 0.50, CHCb); 1H NMR (500 MHz, CDCI3): 8 0.68 (d, 3H, J = 6.0 Hz, CH3), 
1.89 (s, 3H, CH3CO), 1.96 (s, 3H, CH3CO), 2.02 (s, 3H, CH3CO), 3. 70-3.74 (m, 2H, H-5u, 
OH), 4.15 (dd, 1H, J = 9.5, 9.5 Hz, H-41), 4.19 (m, 1H, H-2\ 4.40 (d, 1H, J = 12.0 Hz, 
Troc-Ha), 4.41 (m, 1 H, H-51), 4.48 (dd, 1 H, J = 12.5, 3.0 Hz, H-61a), 4.65 (d, 1 H, J = 12.0 
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Hz, Troc-Hb), 4.87-4.94 (m, 3H, H-411 , H-1 1, H-61b), 5.13-5.18 (m, 2H, H-2", H-311 ), 5.36 
(brs, 1 H, H-1n), 5.75 (dd, 1 H, J = 11.0, 10.5 Hz, H-31), 5.78 (d, 1 H, J = 10.0 Hz, NH), 7.40-
7.62 (m, 6H, 6Ar-H), 8.08 (m, 4H, 4Ar-H); 13C NMR (125 MHz, CHCb): 817.04, 20.99, 
54.91' 62.74, 67.60, 68.95, 69.41' 70.16, 70.52, 72.12, 74.47, 75.91' 92.1 0, 95.31' 98.36, 
128.54, 128.70, 129.58, 130.03, 130.35, 133.46, 133.63, 154.70, 166.29, 166.59, 170.05, 
170.32, 170.58; Anal. Calcd for C3sH3aCbN01 6: C, 50.34; H, 4.59; N, 1.68. Found: C, 
50.31; H, 4.55; N, 1.52. 
For structure confirmation that 24 was rhamnosylated at 4-0H, 24 was converted into the 
acetate 26. To a cooled solution (ice water bath) of 24 (78 mg, 0.09 mmol) in pyridine (2.1 
mL), acetic anhydride (1.7 mL) was added. The mixture was stirred at room temperature 
for 4 h. The solution was diluted with CH2Ciz (150 mL) and washed successively with cold 
HCI solution (4 N, 20 mL), and saturated NaHC03 solution (20 mL x 3). The organic layer 
was dried over anhydrous NaS04 and concentrated under vacuum. The residue was 
subjected to flash column chromatography (hexane/ethyl acetate, 1.5:1) to give 
compound 26 (70 mg, 86%) as a white solid. Rt 0.73 (CH2CI2/MeOH, 25:1); 1H NMR (500 
MHz, CDCb): 8 0.67 (d, 3H, J = 6.0 Hz, CH3), 1.91 (s, 3H, CH3CO), 1.97 (s, 3H, CH3CO), 
2.01 (s, 3H, CH3CO), 2.28 (s, 3H, CH3CO), 3.70 (m, 1H, H-5n), 4.17 (dd, 1H, J = 9.5, 10.0 
Hz, H-41), 4.18 (m, 1 H, H-2'), 4.33 (m, 1 H, H-51), 4.39 (d, 1 H, J = 12.0 Hz, Troc-Ha), 4.51 
(dd, 1 H, J = 12.5, 2.5 Hz, H-61a), 4.67 (d, 1 H, J = 12.0 Hz, Troc-Hb), 4.75 (m, 1 H, H-61b), 
4.89 (dd, 1 H, J = 1 0.0, 9.5 Hz, H-41\ 4.90 (brs, 1 H, H-1n), 5.15 (m, 3H, H-2'1, H-3", NH) 
5.65 (dd, 1 H, J = 11.0, 10.5 Hz, H-3\ 6.24 (d, 1 H, J = 3.5 Hz, H-1 1), 7.42-7.50 (m, 4H, 4 
Ar-H), 7.59 (m, 2H, 2 Ar-H), 8.05 (m, 4H, 4 Ar-H). 
2, 3, 4-Tri-0-acetyl-a-L-rhamnopyranosyl-(1-4 )-3, 6-di-0-benzoy/-2-deoxy-2-(2, 2, 2-
trich/oroethoxycarbonylamino)-0-a-o-glucopyranosy/ trichloroacetimidate (27): 
~ Ac~ TrocHNoC(NH)CCI3 
AcO OAc 
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To a solution of 24 (500 mg, 0.58 mmol) in anhydrous CH2Cb (3 ml), trichloroacetonitrile 
(CCbCN, 1.0 ml, 9.97 mmol) and cesium carbonate (Cs2C03, 377 mg, 1.16 mmol) were 
added and stirred for 20 min at room temperature. The solvent was removed in vacuo and 
the residue was purified with flash column chromatography (hexane/EtOAc/EhN, 
1.5:1 :0.05) to afford compound 27 (466 mg, 80%) as a white solid. R, 0.29 
(hexane/EtOAc, 1.5:1 ); [a]~ +26.2 (c 0.50, CHCb); 1H NMR (500 MHz, CDCb): 8 0.68 (d, 
3H, J = 6.0 Hz, CH3), 1.90 (s, 3H, CH3CO), 1.96 (s, 3H, CH3CO), 2.01 (s, 3H, CH3CO), 
3. 71 (m, 1 H, H-5n), 4.22 (dd, 1 H, J = 9.5, 9.5 Hz, H-4\ 4.30 (m, 1 H, H-51), 4.42 (m, 1 H, H-
2\ 4.48 (d, 1 H, J = 12.0 Hz, Troc-Ha), 4.53 (dd, 1 H, J = 12.5, 3.5 Hz, H-61a), 4.63 (d, 1 H, 
J= 12.0 Hz, Troc-Hb), 4.79 (dd, 1H, J= 12.5, 1.5 Hz, H-61b), 4.88 (dd, 1H, J= 10.0, 10.0 
Hz, H-4\ 4.91 (brs, 1 H, H-1 rr), 5.15 (m, 1 H, H-2n), 5.17 (dd, 1 H, J = 1 0.0, 3.5 Hz, H-3rr), 
5.22 (d, 1 H, J = 10.0 Hz, NH), 5.71 (dd, 1 H, J = 11.0, 9.5 Hz, H-31), 6.42 (d, 1 H, J = 3.5 
Hz, H-1\ 7.47 (m, 4H, 4 Ar-H), 7.60 (m, 2H, 2 Ar-H), 8.06 (m, 4H, 4 Ar-H), 8.81 (s, 1 H, 
NH); 13C NMR (125 MHz, CHCb): 817.06, 20.88, 20.92, 20.96, 54.46, 62.20, 67.68, 
68.58, 70.11 I 70.74, 71.66, 71.85, 74.61 I 75.89, 90.83, 94.87, 95.09, 99.03, 128.65, 
128.69, 129.19, 129.81, 129.99, 130.25, 133.43, 133.92, 154.44, 160.70, 165.94, 166.73, 
170.01 I 170.20; Anal. Calcd for c37H3aC16N2016: C, 45.37; H, 3.91; N, 2.86. Found: C, 
45.12; H, 3.32; N, 2.33. 
Diosgenyl 2, 3, 4-tri-0-acetyl-a-L-rhamnopyranosy/-(1-4)-3, 6-di-0-benzoy/-2-deoxy-2-





Method 1: A suspension of 27 (230 mg, 0.22 mmol), diosgenin 2 (95 mg, 0.22 mmol), and 
activated molecular sieves (4 A, 2.0 g) in anhydrous CH2Cb (3 ml) was stirred at room 
temperature for 15 min under N2 atmosphere. A solution of trimethylsilyl 
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trifluoromethanesulfonate (TMSOTf, 0.45 ml, 0.01 M in dry CH2Cb) was added drop-
wise. The mixture was stirred for 15 min, quenched by saturated NaHC03 solution (1 0 
ml), extracted with CH2Cb (3 x 1 0 ml) and dried over NaS04. The filtrate was 
concentrated in vacuo with the resulting residue purified by flash column chromatography 
(hexane/EtOAc/MeOH, 5:2:0.05) to give compound 28 (221 mg, 80%) as a white foam. 
Method 2: A suspension of 30 (230 mg, 0.22 mmol), 23 (191 mg, 0.44 mmol), and 
activated molecular sieves (4 A, 2.0 g) in anhydrous CH2Cb (5 ml) was stirred at room 
temperature for 15 min under N2 atmosphere. A solution of trimethylsilyl 
trifluoromethanesulfonate (TMSOTf, 0.44 ml, 0.01 M in dry CH2Cb) was added drop-
wise. The mixture was stirred for 30 min, quenched by saturated NaHC03 solution (5 ml), 
extracted with CH2Cb (3 x 20 ml) and dried over NaS04. The filtrate was concentrated in 
vacuo with the resulting residue purified by flash column chromatography 
(hexane/EtOAc/MeOH, 5:2:0.05) to give compound 28 (262 mg, 94%) as a white foam. 
Rr 0.17 (hexane/EtOAc/MeOH, 6:2:0.05); [a]2~ -52.5 (c 0.20, CHCb); 1H NMR (500 MHz, 
CDCb): 8 0.67 (d, 3H, J = 6.0 Hz, CH3), 0.77 (s, 3H, CH3), 0.79 (d, 3H, J = 6.0 Hz, CH3), 
0.95 (s, 3H, CH3), 0.98 (d, 3H, J = 6.5 Hz, CH3), 1.91 (s, 3H, CH3CO), 1.95 (s, 3H, 
CH3CO), 2.00 (s, 3H, CH3CO), 3.38 (dd, 1 H, J = 11.5, 10.5 Hz, H-26a), 3.48 (m, 2H, H-
26b, H-3), 3.69 (m, 1 H, H-5n), 3.75 (dd, 1 H, J = 9.0, 9.5 Hz, H-21), 3.86 (m, 1 H, H-51), 4.04 
(dd, 1 H, J = 9.0, 9.5 Hz, H-41), 4.41 (approx. q, 1 H, J:::: 7.5 Hz, H-16), 4.52 (dd, 1 H, J = 
12.0, 5.0 Hz, H-61a), 4.54 (d, 1 H, J = 12.0 Hz, Troc-Ha), 4.71 (d, 1 H, J = 12.0 Hz, Troc-
Hb), 4.77 (d, 1 H, J = 8.0 Hz, H-1\ 4.80 (dd, 1 H, J = 12.5, 2.5 Hz, H-61b), 4.87 (brs, 1 H, H-
111), 4.88 (dd, 1 H, J = 1 0.0, 9.5 Hz, H-411), 5.12 (m, 1 H, H-211), 5.15 (dd, 1 H, J = 1 0.0, 3.5 
Hz, H-311), 5.29 (m, 1 H, H-6), 5.60 (dd, 1 H, J = 1 0.5, 9.0 Hz, H-31), 7.45 (m, 4H, 4 Ar-H), 
7.58 (m, 2H, 2Ar-H), 8.05 (m, 4H, 4Ar-H); 13C NMR (125 MHz, CHCI3): 814.74, 16.48, 
17.02, 17.35, 19.53, 20.91, 28.98, 29. 71, 30.49, 31.56, 32.03, 32.25, 36.96, 37.18, 39.01, 
39.95, 40.45, 41.78, 50.16, 56.67, 57.17, 62.25, 62.99, 67.05, 67.66, 68.65, 70.19, 70.73, 
73.25, 73.45, 74.49, 80.17, 81.01, 95.50, 98.89, 99.88, 109.51, 121.99, 128.60, 128.67, 
129.52, 130.02, 130.22, 133.28, 133.72, 140.49, 154.35, 166.06, 166.39, 170.05, 170.16, 
170.26; Anal. Calcd for C62H78CbN01e: C, 60.46; H, 6.38; N, 1.14. Found: C, 60.14; H, 
6.48; N, 0.89. 
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Compound 3 (2.88 g, 3.29 mmol) was dissolved in a stock solution composed of 
guanidine nitrate (3.72 g, 30.4 mmol) and NaOMe (1.0 M, 6 ml) in MeOH/CH2Cb (9:1, 
300 ml). After stirring for 20 h at room temperature, the mixture was neutralized by 
adding weak acidic ion-exchange resin (Amberlite IRC-50, H+ form). The resin was filtered 
and the filtrate concentrated in vacuo. The solid was subjected to flash column 
chromatography (CH2Cb/MeOH, 12.5:1) to give compound 29a (2.21 g, 90%) as a white 
solid. The compound was freeze dried in dioxane to ensure removal of residual methanol 
which interferes with the subsequent reaction. Rt 0.19 (CH2Cb/MeOH, 14.3:1 ); [a]~ -45.0 
(c 0.5, MeOH); 1H NMR (500 MHz, C505N): 8 0.70 (d, 3H, J = 5.5 Hz, CH3), 0.84 (s, 3H, 
CH3), 0.92 (s, 3H, CH3), 1.15 (d, 3H, J = 7.0 Hz, CH3), 2.49 (m, 1 H), 2.62 (m, 1 H), 3.51 
(dd, 1H, J= 10.0, 11.0 Hz, H-26'a), 3.60 (dd, 1H, J= 10.0, 3.5 Hz, H-26'b), 3.85 (m, 1H, 
H-3'), 4.05 (m, 1 H, H-5), 4.30 (dd, 1 H, J = 9.0, 9.0 Hz, H-4 ), 4.33 (dd, 1 H, J = 1 0.0, 9.0 
Hz, H-3), 4.42-4.49 (m, 2H, H-2, H-6a), 4.55 (approx. q, 1 H, J:::: 7.5 Hz, H-16'), 4.61 (brd, 
1H, J= 11.5 Hz, H-6b), 4.95 (d, 1H, J= 12.0 Hz, Troc-Ha), 5.17 (d, 1H, J= 12.0 Hz, Troc-
Hb), 5.18 (m, 1H, H-6'), 5.22 (d, 1H, J= 8.0 Hz, H-1), 6.61 (brs, 1H, OH), 7.52 (brs, 1H, 
OH), 7.59 (brs, 1 H, OH), 9.26 (d, 1 H, J = 9.0 Hz, NH); 13C NMR (125 MHz, C505N): 
815.39, 16.69, 17.68, 19.79, 21.42, 29.60, 30.44, 30.94, 31.94, 32.14, 32.53, 37.35, 
37.70, 39.79, 40.18, 40.78, 42.30, 50.54, 56.95, 60.17, 63.10, 63.21, 67.20, 67.54, 72.64, 
74.94, 76.60, 79.04, 81.42, 97.50, 101.47, 109.61, 121.98, 141.22, 156.20; Anal. Calcd for 
C35H54CbNOg: C, 57.56; H, 7.25; N, 1.86. Found: C, 56.61; H, 6.41; N, 1.67. 
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To a solution of 29a (386 mg, 0.51 mmol) and 4-dimethylaminopyridine (DMAP) (6 mg, 
0.05 mmol) in anhydrous pyridine (4 ml) and CHzCb (2 ml), benzoyl chloride (0.12 ml, 
1.03 mmol) in dry CH2Cb (2 ml) was added drop-wise under N2 atmosphere at -40 °C. 
The reaction was carefully monitored by TLC every fifteen minutes. After being stirred at 
room temperature for 2 h, the mixture was quenched with MeOH. The solution was then 
diluted with CH2Cb (150 ml) and washed with cold HCI solution (4 N, 30 ml) and 
saturated NaHC03 solution (30 ml). The organic layer was dried over anhydrous NaS04 
and concentrated under vacuum. The residue was subjected to flash column 
chromatography (toluene/acetone, 11:1) to give compound 30 (340 mg, 69%) as a white 
solid. Rt 0.24 (toluene/acetone, 11:1 ); [a]~ -33.5 (c 0.20 CHCb); 1H NMR (500 MHz, 
CDCb): 8 0.78 (s, 3H, CH3), 0.79 (d, 3H, J = 6.5 Hz, CH3), 0.97 (s, 3H, CH3), 0.98 (d, 3H, 
J = 8.0 Hz, CH3), 3.38 (dd, 1 H, J = 11.0, 11.0 Hz, H-26'a), 3.40 (brs, 1 H, OH), 3.48 (dd, 
1 H, J = 11.5, 3.5 Hz, H-26'b), 3.53 (m, 1 H, H-3'), 3.75-3.81 (m, 3H, H-2, H-4, H-5), 4.41 
(approx. q, 1 H, J;::: 7.5 Hz, H-16'), 4.57 (d, 1 H, J = 12.0 Hz, Troc-Ha), 4.63 (d, 1 H, J = 
12.5, 1.5 Hz, H-6a), 4.71 (d, 1H, J = 12.0 Hz, Troc-Ha) 4.72 (m, 1H, H-6b), 4.83 (d, 1H, J 
= 8.5 Hz, H-1 ), 5.27 (m, 1 H, H-6'), 5.40 (d, 1 H, J = 9.0 Hz, NH), 5.50 (dd, 1 H, J = 1 0.0, 8.5 
Hz, H-3), 7.38-7.45 (m, 4H, 4 Ar-H), 7.56 (m, 2H, 2 Ar-H), 8.02 (m, 4H, 4 Ar-H); 13C NMR 
(125 MHz, CHCb): 814.75, 16.49, 17.35, 19.56, 21.00, 28.98, 29.72, 30.49, 31.56, 32.03, 
32.25, 36.99, 37.25, 39.03, 39.97, 40.46, 41. 78, 50.21 J 56.56, 56.68, 62.26, 63.99, 67.05, 
70.02, 74.23, 74.48, 75.81 I 80.1 0, 81.00, 95.611 99.90, 109.53, 121.99, 128.62, 128.68, 
129.17, 129.80, 130.10, 130.25, 133.50, 133.85, 140.51, 154.46, 167.21, 167.51;Anal. 
Calcd for Cs0H62CbN011: C, 62.60; H, 6.51; N, 1.46. Found: C, 63.01; H, 6.32; N, 1.1 0. 
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To a solution of 28 (217 mg, 0.17 mmol) in acetic acid (10 ml), zinc dust (2.0 g) was added 
and the mixture was stirred at room temperature for 20 h. The mixture was filtered and the 
solid was thoroughly washed with CH2Cb (1 00 ml). The filtrate was concentrated in vacuo 
and the residue was re-dissolved with CH2Cb (200 ml). The solution was washed with 
saturated NaHC03 solution (20 ml), dried with Na2S04, and concentrated under vacuum 
to give a white solid 32 (180 mg, 96%) which was used without further purification in the 
next step. 
Diosgenyl 2, 3, 4-tri-0-acety/-a-L-rhamnopyranosy/-( 1 -4 )-2-benzamido-3, 6-di-0-benzoy/-





To a cooled solution (ice water bath) of 32 (85 mg, 0.08 mmol) in pyridine (2.0 ml), 
benzoyl chloride (14.0 ).!L, 0.12 mmol) was added drop-wise. The mixture was stirred at 
room temperature for 4 h. The solution was diluted with CH2Cb (150 ml), washed with 
cold HCI solution (4 N, 20 ml) and saturated NaHC03 solution (20 ml). The organic layer 
was dried over anhydrous NaS04 and concentrated under vacuum. The residue was 
subjected to flash column chromatography (toluene/acetone, 9:1) to give compound 33 
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(92 mg, 80%) as a white solid. Rt 0.25 (toluene/acetone, 9:1); [af~ -33.9 (c 1.0 CHCb); 1H 
NMR (500 MHz, CDCb): 8 0.69 (d, 3H, J = 6.0 Hz, CH3), 0.76 (s, 3H, CH3), 0.79 (d, 3H, J 
= 6.5 Hz, CH3), 0.92 (s, 3H, CH3), 0.97 (d, 3H, J = 7.0 Hz, CH3), 1.90 (s, 3H, CH3CO), 
1.95 (s, 3H, CH3CO), 2.01 (s, 3H, CH3CO), 3.37 (dd, 1 H, J = 1 0.5, 11.5 Hz, H-26a), 3.49 
(m, 2H, H-26b, H-3), 3.72 (m, 1 H, H-5n), 3.93 (m, 1 H, H-51), 4.14 (dd, 1 H, J = 9.0, 9.5 Hz, 
H-41), 4.27 (dd, 1 H, J = 9.0, 9.0 Hz, H-i), 4.40 (approx. q, 1 H, J::::: 7.0 Hz, H-16), 4.55 (dd, 
1H, J= 12.0, 5.0 Hz, H-61a), 4.83 (dd, 1H, J= 12.0, 2.0 Hz, H-61b), 4.88 (dd, 1H, J= 10.0, 
10.0 Hz, H-4n), 4.91 (d, 1 H, J = 8.5 Hz, H-1 1), 4.92 (brs, 1 H, H-1 n), 5.16 (m, 1 H, H-2n), 
5.17 (m, 1 H, H-3n), 5.21 (m, 1 H, H-6), 5.71 (dd, 1 H, J = 8.5, 9.0 Hz, H-31), 6.24 (d, 1 H, J = 
9.0 Hz, NH), 7.28-7.60 (m, 11 H, 11 Ar-H), 8.00 (m, 2H, 2 Ar-H), 8.08 (m, 2H, 2 Ar-H); 13C 
NMR (125 MHz, CHCh): o 14.73, 16.46, 17.02, 17.34, 19.50, 20.91, 28.98, 29.71, 30.48, 
31.53, 32.02, 32.22, 36.93, 37.21, 39.14, 39.93, 40.43, 41.77, 50.16, 55.51, 56.65, 62.24, 
63.11, 67.03, 67.61, 68.73, 70.17, 70.76, 73.27, 74.02, 76.81, 79.94, 80.99, 98.67, 
100.22, 109.49, 128.61, 128.73, 129.53, 130.04, 130.15, 131.65, 133.26, 133.60, 134.65, 
140.64, 166.12, 166.92, 168.06, 170.04, 170.18, 170.23; ESI-LRMS m/z: found 1182 [M + 
Nat; ESI-HRMS m/z: [M +Nat Calcd for CssHa1N017Na: 1182.5396, found: 1182.5394. 
Diosgenyl 2, 3, 4-tri-0-acetyl-a-L-rhamnopyranosy/-(1-4)-3, 6-di-0-benzoyl-2-deoxy-2-{5-
[(R/S)-1,2-dithio/an-3-yl]-pentanamido}-P-D-glucopyranoside (34): 
To a solution of 32 (95 mg, 0.09 mmol) in dry DMF (5.0 ml), (±)-a-lipoic acid (18 mg, 0.09 
mmol), DIPEA (0.03 ml, 0.17 mmol), and HBTU (33 mg, 0.09 mmol) were added and the 
mixture was stirred for 16 h. The solvent was removed in vacuo and the residue was 
dissolved with CH2Ciz (150 ml) and washed with H20 (1 0 ml x 2). The organic layer was 
dried over anhydrous NaS04 and concentrated under vacuum. The residue was subjected 
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to flash column chromatography (toluene/acetone, 9:1) to give compound 34 (92 mg, 
83%) as a white solid and as a diastereomeric mixture (R/S, 1:1 ). Rt 0.29 
(toluene/acetone, 9:1); [a]~ -50.7 (c 0.33 CHCb); 1H NMR (500 MHz, CDCb): o 0.68 (d, 
3H, J = 6.0 Hz, CH3), 0.78 (s, 3H, CH3), 0.79 (d, 3H, J = 6.5 Hz, CH3), 0.95 (s, 3H, CH3), 
0.98 (d, 3H, J = 7.0 Hz, CH3), 1.91 (s, 3H, CH3CO), 1.95 (s, 3H, CH3CO), 2.00 (s, 3H, 
CH3CO), 3.03-3.15 (m, 2H, CH2S), 3.31 (m, 1H), 3.37 (dd, 1H, J = 11.0, 11.0 Hz, H-26a), 
3.47 (m, 2H, H-26b, H-3), 3.69 (m, 1 H, H-511 ), 3.86 (m, 1 H, H-51), 4.04 (m, 1 H, H-21), 4.05 
(dd, 1 H, J = 9.0, 9.5 Hz, H-41), 4.42 (approx. q, 1 H, J ~ 7.5 Hz, H-16), 4.51 (dd, 1 H, J = 
12.0, 5.0 Hz, H-61a), 4.78 (two sets of d, each 0.5H, J = 8.0 Hz, H-1\ 4.79 (dd, 1 H, J = 
12.0, 2.5 Hz, H-61b), 4.87 (brs, 1 H, H-1n), 4.88 (dd, 1 H, J = 9.5, 9.5 Hz, H-4n), 5.14 (m, 
1 H, H-2n), 5.15 (m, 1 H, H-3n), 5.28 (m, 1 H, H-6), 5.54 (d, 1 H, J = 9.0 Hz, NH), 5.56 (m, 
1 H, H-3\ 7.45 (m, 4H, 4 Ar-H), 7.58 (m, 2H, 2 Ar-H), 8.05 (m, 4H, 4 Ar-H); 13C NMR (125 
MHz, CHCb): 814.72, 16.47, 17.01, 17.33, 19.53, 20.90, 20.95, 25.35, 28.76, 28.98, 
29.71' 30.48, 31.56, 32.03, 32.26, 34.66, 36.64, 36.95, 37.20, 38.57, 39.22, 39.94, 40.29, 
40.44, 41.78, 50.17, 54.98, 56.27, 56.67, 62.26, 63.07, 67.04, 67.59, 68.72, 70.15, 70.74, 
73.17, 73.89, 76.80, 79.72, 80.99, 98.62, 99.90, 109.49, 121.92, 128.58, 128.72, 129.61' 
130.01, 130.18, 133.25, 133.67, 140.58, 166.08, 166.68, 170.02, 170.16, 170.22, 172.96; 
ESI-LRMS m/z: found 1267 [M + Nar; ESI-HRMS m/z: [M + Nar Calcd for 
C67HagN017S2Na: 1266.5469, found: 1266.5463. 
Diosgenyl 2, 3, 4-tri-0-acety/-a-L -rhamnopyranosyl-( 1 -4)-3, 6-di-0-benzoy/-2-deoxy-2-(3-
nitrobenzamido )-~-o-glucopyranoside (35 ): 
~0 -- J Z NH 
Ac~ q AcO OAc -
~ !! 
02N 
To a solution of 32 (150 mg, 0.14 mmol) in dry DMF (5.0 ml), 3-nitrobenzoic acid (28 mg, 
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0.16 mmol), DIPEA (0.05 mL, 0.28 mmol), and HBTU (53 mg, 0.14 mmol) were added 
and the mixture was stirred for 16 h. The solvent was removed in vacuo and the residue 
was dissolved with CH2Cb (150 mL) and washed with H20 (1 0 mL x 2). The organic layer 
was dried over anhydrous NaS04 and concentrated under vacuum. The residue was 
subjected to flash column chromatography (toluene/acetone, 11:1) to give compound 35 
(143 mg, 83%) as a pale yellow solid. Rt0.28 (toluene/acetone, 11:1); [a]~ -29.8 (c 1.0 
CHCb); 1H NMR (500 MHz, CDCb): 8 0.72 (d, 3H, J = 6.5 Hz, CH3), 0.76 (s, 3H, CH3), 
0.79 (d, 3H, J = 6.5 Hz, CH3), 0.91 (s, 3H, CH3), 0.97 (d, 3H, J = 7.0 Hz, CH3), 1.90 (s, 3H, 
CH3CO), 1.95 (s, 3H, CH3CO), 2.02 (s, 3H, CH3CO), 3.37 (dd, 1H, J = 11.0, 11.0 Hz, H-
26a), 3.47 (m, 1 H, H-26b) 3.53 (m, 1 H, H-3), 3.73 (m, 1 H, H-5n), 3.98 (m, 1 H, H-51), 4.19 
(dd, 1 H, J = 9.0, 9.0 Hz, H-41), 4.36 (dd, 1 H, J = 9.0, 9.0 Hz, H-21), 4.40 (approx. q, 1 H, J::: 
7.0 Hz, H-16), 4.55 (dd, 1 H, J = 12.5, 5.0 Hz, H-61a), 4.88 (m, 1 H, H-61b), 4.90 (dd, 1 H, J = 
9.5, 10.0 Hz, H-4n), 4.95 (brs, 1H, H-1 11), 4.96 (d, 1H, J = 8.0 Hz, H-1 1), 5.15 (m, 2H, H-211 , 
H-311), 5.19 (m, 1 H, H-6), 5.71 (dd, 1 H, J = 9.0, 9.0 Hz, H-31), 6.69 (d, 1 H, J = 9.0 Hz, NH), 
7.39 (m, 1 H, 1 Ar-H), 7.46-7.61 (m, 6H, 6 Ar-H), 7.94 (m, 1 H, 1 Ar-H), 8.02 (m, 2H, 2 Ar-
H), 8.08 (m, 2H, 2 Ar-H), 8.25 (m, 1 H, 1 Ar-H), 8.42 (m, 1 H, 1 Ar-H); 13C NMR (125 MHz, 
CHCb): 814.72, 16.46, 17.05, 17.34, 19.49, 20.92, 20.97, 28.98, 29.75, 30.48, 31.51, 
31.56, 32.03, 32.22, 36.90, 37.19, 39.34, 39.93, 40.42, 41.77, 50.16, 55.56, 56.64, 62.23, 
63.00, 67.02, 67.64, 68.82, 70.09, 70.66, 73.24, 74.18, 76.32, 79.71' 80.97, 98.53, 99.99, 
109.47, 121.92, 122.04, 126.24, 128.64, 128.69, 129.28, 129.98, 130.06, 130.18, 133.15, 
133.35, 133.82, 136.13, 140.44, 148.27, 165.63, 166.19, 167.13, 170.01, 170.26, 170.35; 
ESI-LRMS m/z: found 1228 [M + Nar; ESI-HRMS m/z: [M + Nar Calcd for 
C56HaoN2019Na: 1227.5252, found: 1227.5240. 
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Diosgenyl 2, 3, 4-tri-0-acety/-a-L-rhamnopyranosy/-( 1-4)-3, 6-di-0-benzoy/-2-deoxy-2-
(3, 5-dinitrobenzamido )-~-o-g/ucopyranoside (36): 
0 
~0 
Ac~ op_=t AcO OAc -
I)_ /; N02 
02N 
To a solution of 32 (150 mg, 0.14 mmol) in dry DMF (5.0 ml), 3,5-dinitrobenzoic acid (34 
mg, 0.16 mmol), DIPEA (0.05 ml, 0.28 mmol), and HBTU (53 mg, 0.14 mmol) were 
added and the mixture was stirred for 18 h. The solvent was removed in vacuo and the 
residue was dissolved with CH2Cb (150 ml) and washed with H20 (1 0 ml x 2). The 
organic layer was dried over anhydrous NaS04 and concentrated under vacuum. The 
residue was subjected to flash column chromatography (toluene/acetone, 11:1) to give 
compound 36 (143 mg, 83%) as a light orange solid. Rt 0.32 (toluene/acetone, 11:1 ); [a]~ 
-25.9 (c 0.5 CHCb); 1H NMR (500 MHz, CDCb): 8 0.73 (d, 3H, J = 6.0 Hz, CH3), 0.76 (s, 
3H, CH3), 0.78 (d, 3H, J = 6.0 Hz, CH3), 0.91 (s, 3H, CH3), 0.96 (d, 3H, J = 6.5 Hz, CH3), 
1.91 (s, 3H, CH3CO), 1.97 (s, 3H, CH3CO), 2.03 (s, 3H, CH3CO), 3.37 (dd, 1 H, J = 11.0, 
11.0 Hz, H-26a), 3.47 (m, 1H, H-26b), 3.54 (m, 1H, H-3), 3.73 (m, 1H, H-511 ), 4.01 (m, 1H, 
H-51), 4.20 (dd, 1 H, J = 9.5, 8.5 Hz, H-41), 4.40 (approx. q, 1 H, J = 7.0 Hz, H-16), 4.41 (m, 
1 H, H-i), 4.55 (dd, 1 H, J = 12.5, 5.0 Hz, H-61a), 4.90 (dd, 1 H, J = 9.5, 10.0 Hz, H-411), 
4.92 (m, 1 H, H-61b), 4.96 (brs, 1 H, H-1 11), 4.97 (d, 1 H, J = 8.0 Hz, H-1 1), 5.13 (m, 1 H, H-
211), 5.14 (dd, 1 H, J = 10.0 Hz, 3.0 Hz, H-311), 5.19 (m, 1 H, H-6), 5.67 (dd, 1 H, J = 9.0, 8.5 
Hz, H-31), 7.01 (d, 1 H, J = 9.0 Hz, NH), 7.38-7.62 (m, 6H, 6 Ar-H), 8.01-8.10 (m, 4H, 4 Ar-
H), 8.80 (d, 2H, J = 2.0 Hz, 2 Ar-H), 9.08 (t, 1 H, J = 2.0 Hz, 1 Ar-H); 13C NMR (125 MHz, 
CHCb): 814.73, 16.48, 17.08, 17.36, 19.49, 20.90, 20.95, 28.99, 29.79, 30.49, 31.51, 
31.57, 32.05, 32.23, 36.90, 37.18, 39.45, 39.93, 40.44, 41.78, 50.17, 55.66, 56.65, 62.25, 
62.92, 67.04, 67.71' 68.86, 70.05, 70.60, 73.22, 74.19, 75.99, 79.60, 80.98, 98.44, 99.74, 
109.50, 121.32, 122.10, 127.43, 128.70, 128.80, 129.03, 129.88, 130.09, 130.20, 133.46, 
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134.07, 137.89, 140.27, 148.78, 163.40, 166.29, 167.27, 170.01, 170.35, 170.55; ESI-
LRMS mlz: found 1273 [M + Nat; ESI-HRMS mlz: [M + Nat Calcd for C55H79N3021 Na: 
1272.5103, found: 1272.5095. 




Compound 33 (50 mg, 0.04 mmol) was dissolved in MeOH/CH2Ciz (2:1, 3 ml) and then 
NaOMe solution in methanol (1.5 ml) was added until pH 10. After stirring for 24 hat 
room temperature, the mixture was neutralized by adding weak acidic ion-exchange resin 
(Amberlite IRC-50, H+ form). The resin was filtered and the filtrate concentrated in vacuo. 
The solid was washed thoroughly with CH2Ciz and then applied to a Sephadex LH-20 gel 
filtration column (MeOH) to yield compound 37 (33 mg, 95%) as a white solid. Rt 0.47 
(CH2Ciz/MeOH, 5:1 ); [a]~ -55.2 (c 0.33, MeOH); 1H NMR (500 MHz, C5D5N): 8 0.68 (d, 
3H, J = 5.0 Hz, CH3), 0.80 (s, 3H, CH3), 0.81 (s, 3H, CH3), 1.13 (d, 3H, J = 7.0 Hz, CH3), 
1.68 (d, 3H, J= 5.5 Hz, CH3), 2.39 (m, 1H), 2.68 (m, 1H), 3.49 (dd, 1H, J = 10.5, 10.5 Hz, 
H-26a), 3.58 (m, 1H, H-26b), 3.78 (m, 1H, H-51), 3.83 (m, 1H, H-3), 4.13 (dd, 1H, J = 12.0, 
4.5 Hz, H-61a), 4.26 (brd, 1H, J= 11.0 Hz, H-61b),4.37 (dd, 1H, J= 9.5, 9.5 Hz, H-31),4.52 
(m, 2H, H-21, H-16), 4.57 (dd, 1H, J = 9.0, 3.0 Hz, H-3rr), 4.63 (dd, 1H, J = 9.0 Hz, 9.5 Hz), 
4.72 (m, 1 H, H-2rr), 4.76 (dd, 1 H, J = 9.5 Hz, 9.5 Hz), 5.02 (m, 1 H, H-21), 5.54 (d, 1 H, J = 
8.5 Hz, H-1 1), 5.71 (m, 1 H, H-6), 5.93 (brs, 1 H, H-1 1\ 7.40 (m, 3H, 3 Ar-H), 8.40 (m, 2H, 2 
Ar-H), 9.57 (d, 1 H, J = 8.0 Hz, NH); 13C NMR (125 MHz, CHCb): 8 13.38, 16.67, 17.66, 
18.83, 19.66, 21.39, 29.57, 30.47, 30.92, 31.90, 32.12, 32.54, 37.28, 37.71, 39.87, 40.14, 
40.75, 42.27, 50.52, 55.42, 56.92, 61.75, 63.17, 67.17, 70.74, 72.97, 73.17, 74.07, 74.35, 
77.67, 79.05, 79.49, 81.41, 100.65, 103.24, 109.59, 122.11, 128.44, 129.00, 131.64, 
137.14, 141.03, 168.84; ESI-LRMS m/z: found 848 [M +Nat; ESI-HRMS m/z: [M +Nat 
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Calcd for C4sHs7N012Na: 848.4560, found: 848.4552. 
Diosgenyl a-L-rhamnopyranosy/-( 1 -4)-2-deoxy-2-{5-[(R/S)-1, 2-dithiolan-3-y/]-
pentanamido}-~-o-g/ucopyranoside (38): 
Compound 34 (50 mg, 0.04 mmol) was dissolved in MeOH/CH2Cb (2: 1, 3 ml) and then 
NaOMe solution in methanol (1.5 ml) was added until pH 10. After stirring for 24 h at 
room temperature, the mixture was neutralized by adding weak acidic ion-exchange resin 
(Amberlite IRC-50, H+ form). The resin was filtered and the filtrate concentrated in vacuo. 
The solid was washed thoroughly with CH2Cb and then applied to a silica gel flash 
chromatography column (DCM/MeOH, 50:1 -+ 5:1) to yield 38 (46 mg, 96%) as a white 
solid and as a diasteromeric mixture (R/S, 1:1). Rt0.53 (CH2Cb/Me0H, 5:1); [a]~ -78.0 (c 
0.1 0, MeOH); 1H NMR (500 MHz, CD30D): o 0.76 (d, 3H, J = 6.5 Hz, CH3), 0.77 (s, 3H, 
CH3), 0.92 (d, 3H, J = 7.0 Hz, CH3), 0.99 (s, 3H, CH3), 1.20 (d, 3H, J = 6.5 Hz, CH3), 2.21 
(m, 2H), 2.30 (m, 1 H), 2.41 (m, 1 H), 3.05 (m, 1 H, CH2S), 3.13 (m, 1 H, CH2S), 3.25-3.31 
(m, 2H, H-26a, H-2\ 3.36 (dd, 1H, J = 10.5, 10.5 Hz, 1H, H-26b), 3.41 (m, 1H, H-51), 3.46 
(m, 1 H, H-3), 3.49-3.64 (m, 5H, H-61a, H-31, H-41, H-61b, H-4II), 3.75-3.79 (m, 2H, H-2n H-
3n), 3.90 (m, 1 H, H-51), 4.35 (approx. q, 1 H, J::::: 7.5 Hz, H-16), 4.54 (two sets of d, each 
0.5H, J = 8.0 Hz, H-1 1), 4.82 (d, 1 H, J = 1.5 Hz, H-1n), 5.33 (m, 1 H, H-6); 13C NMR (125 
MHz, CD30D): o 15.03, 16.92, 17.65, 17.99, 20.09, 22.11, 27.02, 30.02, 30.13, 30.78, 
31.58, 32.54, 32.88, 33.32, 40.39, 41.04, 41.46, 41.56, 43.04, 51.74, 57.69, 57.91, 70.76, 
72.34, 72.57, 73.85, 74.58, 76.99, 80.21, 82.35, 101.02, 103.10, 110.73, 122.91, 141.98, 
176.47; ESI-LRMS m/z: found 932 [M +Nat; ESI-HRMS m/z: [M +Nat Calcd for 








In a similar way as described for the preparation of 38, compound 35 (50 mg, 0.04 mmol) 
was converted to 39 (32 mg, 92%) as a white solid. Rt 0.50 (CH2Cb/MeOH, 5:1 ); [a]~ -
41.8 (c 0.50, MeOH); 1H NMR (500 MHz, C50 5N): 8 0.75-0.76 (m, 6H, 2 CH3), 0.91 (d, 3H, 
J = 7.0 Hz, CH3), 0.92 (s, 3H, CH3), 1.21 (d, 3H, J = 6.5 Hz, CH3), 3.27 (dd, 1 H, J = 1 0.5, 
11.5 Hz, H-26a), 3.28 (m, 1 H, H-21), 3.38 (dd, 1 H, J = 1 0.0, 9.5 Hz, 1 H, H-26b), 3.39 (m, 
1 H, H-51), 3.49 (m, 1 H, H-3), 3.57-3.60 (m, 2H, H-31, H-61a), 3.68 (dd, 1 H, J = 12.0, 4.0 
Hz, H-61b), 3. 75-3.87 (m, 4H, H-41, H-2n, H-3n, H-4n), 3.93 (m, 1 H, H-511 ), 4.34 (approx. q, 
1 H, J:::: 7.5 Hz, H-16), 4.70 (d, 1 H, J = 8.5 Hz, H-1 1), 5.24 (m, 1 H, H-6), 7.72 (t, 1 H, J = 8.0 
Hz, Ar-H), 8.20 (m, 1 H, 1 Ar-H), 8.38 (m, 1 H, 1 Ar-H), 8.69 (m, 1 H, 1 Ar-H); The H-1 n peak 
is most likely buried under the solvent peak at 8 4.87. 13C NMR (125 MHz, CD30D): 
815.04, 16.91, 17.65, 17.97, 19.92, 22.10, 30.02, 30.80, 31.58, 32.54, 32.86, 33.25, 
38.07, 38.57, 40.35, 41.02, 41.54, 43.02, 51.74, 57.90, 58.80, 62.12, 63.86, 67.99, 70.77, 
72.36, 72.58, 73.87, 74.46, 77.15, 80.13, 80.63, 82.32, 101.26, 103.13, 110.71, 122.85, 
123.42, 127.18, 131.26, 134.56, 138.14, 141.84, 149.79, 168.49; ESI-LRMS m/z: found 
893 [M + Nat; ESI-HRMS m/z: [M + Nat Calcd for C4sHssN2014Na: 893.4411, found: 
893.4403. 
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In a similar way as described for the preparation of 38, compound 36 (62 mg, 0.05 mmol) 
was converted to 40 (42 mg, 91%) as a white solid. Rt 0.55 (CH2Cb/MeOH, 5:1); [a]~ -
58.0 (c 0.10, MeOH); 1H NMR (500 MHz, CD30D): 8 0.74 (s, 3H, CH3), 0.75 (d, 3H, J = 
6.0 Hz, CH3), 0.90 (d, 3H, J = 7.0 Hz, CH3), 0.92 (s, 3H, CH3), 1.20 (d, 3H, J = 6.0 Hz, 
CH3), 3.27 (m, 2H, H-21, H-26a), 3.37 (dd, 1 H, J = 1 0.0, 9.5 Hz, 1 H, H-26b), 3.38 (m, 1 H, 
H-5\ 3.50 (m, 1H, H-3), 3.57-3.60 (m, 2H, H-31, H-61a), 3.68 (dd, 1H, J = 12.0, 4.0 Hz, H-
61b), 3.74-3.87 (m, 4H, H-4\ H-i1, H-3n, H-4n), 3.92 (m, 1 H, H-5n), 4.33 (approx. q, 1 H, J 
:::::: 7.5 Hz, H-16), 4.70 (d, 1 H, J = 8.0 Hz, H-1 1), 5.25 (m, 1 H, H-6), 9.04 (d, J = 2.0 Hz, 2 Ar-
H), 9.11 (t, 1 H, J = 2.0 Hz, 1 Ar-H); The H-1n peak is most likely buried under the solvent 
peak at 8 4.87. 13C NMR (125 MHz, CD30D): 8 15.03, 16.89, 17.65, 17.96, 19.91, 22.09, 
30.01, 30.80, 31.58, 32.54, 32.86, 33.25, 38.07, 38.56, 40.34, 41.02, 41.53, 43.02, 51.74, 
57.89, 59.02, 62.09, 63.85, 67.98, 70.77, 72.36, 72.57, 73.85, 74.47, 77.20, 80.03, 80.51' 
82.32, 101.04, 103.17, 110.71, 122.19, 122.91, 128.59, 139.53, 141.79, 150.25, 166.09; 
ESI-LRMS m/z: found 938 [M + Naf; ESI-HRMS m/z: [M + Naf Calcd for C46H6sN3015Na: 
938.4262, found: 938.4256. 
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4.3 Cell lines, cell culture, and medium 
Cell lines used in this study include SK-N-SH (neuroblastoma), MCF-7 (breast cancer), 
and HeLa (cervical cancer). SK-N-SH and MCF-7 cell lines were supplied by the 
American Type Culture Collection (Manassas, Virginia), and HeLa cells were obtained 
from the Lady Davis Institute for Medical Research (Montreal, Quebec). All cell lines were 
grown in Dulbecco's modified Eagle's medium (Sigma) containing 10% fetal bovine serum 
(PAA Laboratories) at 37 oc in a 5% C02 humidified atmosphere. 
4.4 Cell proliferation assay 
Measurement of cell proliferation was performed using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay as described by Carmichael et al. 92 Briefly, 
2000 cells were plated out into each well of a 96-wellplate and allowed to adhere. Saponin 
analogues (dissolved in DMSO (Sigma) and diluted with tissue culture medium) were 
added at increasing concentrations (0-30 J.!M, 8 wells per concentration). The cells were 
incubated in the presence of each saponin analogue for 72 h. MTT reagent (Sigma) 
dissolved in phosphate-buffered saline was added to each well at a concentration of 0.5 
mg/mL, and the cells were incubated for four additional hours. Following this time, the 
medium containing the MTT reagent was aspirated, and DMSO (1 00 J.!L) was added to 
each well. The absorbance of each well was measured in a microplate reader 
(PowerWave Xs, Bio-Tek) at a wavelength of 490 nm. The ICso value for each compound 
tested was determined by plotting concentration vs. percent absorbance obtained in the 
MTT assay. The IC50 results listed in Table 1 represent the average ICso value obtained 
from multiple MTT assays for each compound. 
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6 APPENDIX 
1 1H NMR Spectrum of 3 80 
2 13C NMR Spectrum of 3 81 
3 1H NMR Spectrum of 5 82 
4 13C NMR Spectrum of 5 83 
5 1H NMR Spectrum of 6 84 
6 13C NMR Spectrum of 6 85 
7 1H NMR Spectrum of 7 86 
8 1H NMR Spectrum of Sa 87 
9 13C NMR Spectrum of Sa 88 
10 1H NMR Spectrum of 9 89 
11 13C NMR Spectrum of 9 90 
12 1H NMR Spectrum of 10 91 
13 13C NMR Spectrum of 10 92 
14 1 H NMR Spectrum of 11 93 
15 13C NMR Spectrum of 11 94 
16 1H NMR Spectrum of 12 95 
17 13C NMR Spectrum of 12 96 
18 1H NMR Spectrum of 13 97 
19 13C NMR Spectrum of 13 98 
20 1H NMR Spectrum of 14 99 
21 13C NMR Spectrum of 14 100 
22 1H NMR Spectrum of 15 101 
23 13C NMR Spectrum of 15 102 
24 1H NMR Spectrum of 16 103 
25 13C NMR Spectrum of 16 104 
26 1H NMR Spectrum of 17 105 
27 13C NMR Spectrum of 17 106 
28 1H NMR Spectrum of 1S 107 
29 13C NMR Spectrum of 1S 108 
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30 1H NMR Spectrum of 20 109 
31 13C NMR Spectrum of 20 110 
32 1H NMR Spectrum of 21 111 
33 13C NMR Spectrum of 21 112 
34 1H NMR Spectrum of 24 113 
35 13C NMR Spectrum of 24 114 
36 1H NMR Spectrum of 26 115 
37 1H NMR Spectrum of 27 116 
38 13C NMR Spectrum of 27 117 
39 1H NMR Spectrum of 28 118 
40 13C NMR Spectrum of 28 119 
41 1H NMR Spectrum of 29a 120 
42 13C NMR Spectrum of 29a 121 
43 1H NMR Spectrum of 30 122 
44 13C NMR Spectrum of 30 123 
45 1H-1H COSY 20 NMR Spectrum of 30 124 
46 1H NMR Spectrum of 33 125 
47 13C NMR Spectrum of 33 126 
48 1 H NMR Spectrum of 34 127 
49 13C NMR Spectrum of 34 128 
50 1H NMR Spectrum of 35 129 
51 13C NMR Spectrum of 35 130 
52 1H NMR Spectrum of 36 131 
53 13C NMR Spectrum of 36 132 
54 1H NMR Spectrum of 37 133 
55 13C NMR Spectrum of 37 134 
56 1H NMR Spectrum of 38 135 
57 13C NMR Spectrum of 38 136 
58 1H NMR Spectrum of 39 137 
59 13C NMR Spectrum of 39 138 
60 1H NMR Spectrum of 40 139 
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ESI-HRMS Calcd for C47H71N011S2Na [M+Nat 912.4360, found (positive mode): 
912.4358. 
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ESI-HRMS Calcd for C66HaoN201 9 [Mf: 1204.5355, found (positive mode): 1205.5428 
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ESI-HRMS Calcd for CssH79N3021 [Mt; 1249.5206, found (positive mode): 1250.5272 
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ESI-HRMS Calcd for C47H75N012S2 [M( 909.4730, found (positive mode): 910.4800 
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ESI-HRMS Calcd for C45H55N2014 [Mt 870.4514, found (positive mode): 871.4583 
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ESI-HRMS Calcd for C4sHssN301 6 [Mf: 915.4364, found (positive mode): 916.4436 
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